

HERBAL MEDICINES FOR DEMENTIA AND ALZHEIMER'S DISEASE



Editors:

Sachin Kumar Jain

Kratika Daniel

Sudha Vengurlekar

Bentham Books

Herbal Medicines for Dementia and Alzheimer's Disease

Edited by

Sachin Kumar Jain

*Oriental College of Pharmacy & Research
Oriental University, Indore
Madhya Pradesh, India*

Kratika Daniel & Sudha Vengurlekar

*Faculty of Pharmacy
Oriental University, Indore
Madhya Pradesh, India*

Herbal Medicines for Dementia and Alzheimer's Disease

Editors: Sachin Kumar Jain, Kratika Daniel & Sudha Vengurlekar

ISBN (Online): 979-8-89881-552-3

ISBN (Print): 979-8-89881-553-0

ISBN (Paperback): 979-8-89881-554-7

© 2026, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore,

in collaboration with Eureka Conferences, USA. All Rights Reserved.

First published in 2026.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal ("**Work**"). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

No. 9 Raffles Place

Office No. 26-01

Singapore 048619

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	ii
LIST OF CONTRIBUTORS	iii
CHAPTER 1 INTRODUCTION TO MEMORY AND NEURODEGENERATIVE DISORDERS	1
<i>Sahana Ghosh, Kapil Juvele and Namita Hegde</i>	
INTRODUCTION	1
NEUROSCIENCE OF MEMORY	2
Types of Memory	3
Process of Memory Formation	3
The Role of Key Brain Regions in Memory Formation	4
Key Neurotransmitters in Memory Formation	6
TYPES OF NEURODEGENERATIVE DISEASES	7
Alzheimer's Disease	9
Parkinson's Disease	10
Amyotrophic Lateral Sclerosis	10
Huntington's Disease	10
Prion Diseases	10
Multiple System Atrophy	11
Spinocerebellar Ataxia	11
Spinal Muscular Atrophy	11
Lewy Body Diseases	12
Friedreich's Ataxia	12
Chronic Traumatic Encephalopathy	12
Frontotemporal Dementia	13
Vascular Dementia	13
Multiple Sclerosis	13
MEMORY DYSFUNCTION IN NEURODEGENERATIVE DISEASES	14
INTERVENTIONS FOR MEMORY IMPAIRMENT MANAGEMENT	15
CONCLUSION	15
REFERENCES	15
CHAPTER 2 AN OVERVIEW OF DEMENTIA AND ALZHEIMER'S	20
<i>Rahul Trivedi, Rajesh A. Maheshwari, Kinjal P. Patel, Shweta Bhandari, Rajesh Hadia, Swapnil Goyal and Rupesh Soni</i>	
INTRODUCTION	20
RISK FACTORS OF DEMENTIA	21
SIGN AND SYMPTOMS	22
Primary Stage	22
Middle Stage	22
Later Stage	22
TYPES OF DEMENTIA	22
ALZHEIMER'S DISEASE	24
CHARACTERISTICS OF AD	27
Amyloid Plaques	27
Neurofibrillary Tangles (NFTs)	28
Neuroinflammation	28
Metal Ion & AD	29
Excitotoxicity of Glutamate	29

Reactive Oxygen Species and AD	30
Cholinergic Neurons & AD	30
CURRENT TREATMENT OF AD	30
CONCLUDING REMARKS	31
ACKNOWLEDGEMENTS	32
DECLARATION	32
REFERENCES	32
CHAPTER 3 NOOTROPICS AND SMART DRUGS: AN OVERVIEW	36
<i>Vaibhav Rajoriya, Ravikant Gupta, Sudha Vengurlekar and Sachin Kumar Jain</i>	
INTRODUCTION	36
Classification	37
TYPES OF NOOTROPICS	37
MECHANISMS OF ACTION	39
BENEFITS OF NOOTROPICS	43
RISKS AND SIDE EFFECTS	44
Severe Side Effects	44
NOOTROPICS FOR DEMENTIA AND ALZHEIMER'S DISEASE	45
ROLE IN DISEASE MANAGEMENT	45
Case Studies	46
Clinical Trials	47
INTEGRATING NOOTROPICS INTO THERAPEUTIC STRATEGIES	47
CURRENT RESEARCH AND DEVELOPMENTS	48
CONCLUSION	48
FUTURE DIRECTIONS IN NOOTROPIC RESEARCH	49
DECLARATION	49
REFERENCES	49
CHAPTER 4 HERBAL DRUGS AND THEIR ACTIVE PHYTOCONSTITUENTS USED FOR THE TREATMENT OF ALZHEIMER'S AND DEMENTIA	53
<i>Sachin K. Jain, Rahul Trivedi, Swapnil Goyal, Arpit Sivchandan, Kajal Mudgal, Palmi Modi and Shweta Gandhi</i>	
INTRODUCTION	54
PATHOPHYSIOLOGY AND CAUSES OF ALZHEIMER'S DISEASE	55
Causes of Alzheimer's Disease	56
Pathophysiology and Causes of Other Dementias	56
MOLECULAR PROCESSES INVOLVED IN NEURODEGENERATION	57
Protein Aggregation	57
Neuroinflammation	58
Mitochondrial Dysfunction	58
Oxidative Stress	58
CONVENTIONAL TREATMENT OF ALZHEIMER'S DISEASE (AD) AND DEMENTIA AND LIMITATIONS	59
Cholinesterase Inhibitor Drugs	59
NMDA Receptor Antagonist Drug: Memantine (Namenda)	59
Combination Therapy	59
Anti-Amyloid Therapy (Newer Approaches) Drugs	59
Symptomatic Treatments	59
LIMITATIONS OF CONVENTIONAL TREATMENTS	60
ROLE OF HERBAL DRUGS IN NEURODEGENERATIVE DISORDERS	60
Mechanisms of Herbal Drugs in Neuroprotection	60
HERBAL DRUGS AND THEIR ACTIVE PHYTOCONSTITUENTS	61

Bacopa monnieri (Brahmi)	61
Mechanisms of Action	61
Ginkgo biloba	62
Mechanisms of Action	62
Withania somnifera (Ashwagandha)	62
Mechanisms of Action	62
Curcuma longa (Turmeric)	63
Mechanisms of Action	63
Centella asiatica (Gotu Kola)	64
Mechanisms of Action	64
Panax ginseng (Ginseng)	64
Mechanisms of Action	65
Salvia officinalis (Sage)	65
Huperzia serrata	66
Mechanism of Action	66
Crocus sativus (Saffron)	67
Mechanism of Action	67
Camellia sinensis (Green tea)	67
Passiflora incarnata (Passionflower)	69
Neuroprotective Mechanisms of Flavonoids in AD and Dementia	69
Harman Alkaloids	69
Neuroprotective Mechanisms of Harman Alkaloids in AD and Dementia	69
MECHANISM OF ACTION OF PHYTOCONSTITUENTS IN NEURODEGENERATIVE DISORDERS	69
Antioxidant and Anti-inflammatory Effects	70
Cholinesterase Inhibition	71
Amyloid- β Plaque Reduction	72
CHALLENGES, LIMITATIONS, AND FUTURE RESEARCH DIRECTIONS FOR NATURAL HERBS IN NEURODEGENERATIVE DISEASES	73
FUTURE RESEARCH	74
CONCLUSION	75
DECLARATION	76
REFERENCES	76
CHAPTER 5 NON-HERBAL APPROACHES BEYOND MEDICATION: COMPLEMENTARY THERAPIES FOR ALZHEIMER'S AND DEMENTIA	80
<i>Monali N. Dumore, Manasi M. Choudhari, Nitin G. Dumore, Shrikant Joshi and Swati Deshmukh</i>	
INTRODUCTION	81
Overview of Alzheimer's Disease	81
Overview of Dementia	81
Limitation for Conventional Treatment	82
Importance of Complementary Therapies	84
MUSIC THERAPY	84
Principles of Music Therapy	85
Benefits of Music Therapy to Alzheimer's and Dementia Patients	85
CASE STUDIES AND RESEARCH FINDINGS	87
ART THERAPY	91
Principle of Art Therapy	91
Benefits of Art Therapy in the treatment of Dementia and Alzheimer's	91
Example of Art Therapy Intervention	93

ANIMAL-ASSISTED THERAPY	94
Principle of Animal-Assisted Therapy	95
Benefits of Animal Assisted Therapy in Dementia and Alzheimer	95
Guideline for Implementing Animal Assisted Therapy	97
EXERCISE AND PHYSICAL ACTIVITY	98
Importance of Exercise for Cognitive	98
Benefits of Exercise for Alzheimer's and Dementia Patients	98
Example of Exercise Program and Intervention	99
MINDFULNESS AND MEDITATION	100
Definition of Mindfulness and Meditation	100
Principle of Mindfulness and Meditation	101
Benefits of Mindfulness and Meditation for Alzheimer's and Dementia Patients	101
Guideline for Implementing Mindfulness and Meditation Intervention	102
SENSORY STIMULATION THERAPIES	103
Definition of Sensory Stimulation Therapy	103
Principle of Sensory Stimulation Therapy	104
Benefits of Sensory Stimulation Therapies	104
Example of Sensory Stimulation Therapy Interventions for Alzheimer's and Dementia	105
CONCLUSION	106
Recap of the Various Complementary Therapies	106
Future Directions for Research and Practice of Complementary Therapies	106
Importance of Integrating Complementary Therapies into Care Plan	107
DECLARATION ON THE USE OF AI	107
REFERENCES	108
 CHAPTER 6 COGNITION-ENHANCING AYURVEDIC REMEDIES: A NATURAL STRATEGY AGAINST ALZHEIMER'S AND DEMENTIA	113
<i>Vaibhav Rajoriya, Ravikant Gupta, Sudha Vengurlekar and Sachin Kumar Jain</i>	
INTRODUCTION	113
Key Concepts of Ayurveda	114
AYURVEDIC CONCEPTS OF COGNITION	115
HERBAL FORMULATIONS FOR COGNITIVE ENHANCEMENT	116
MECHANISMS OF ACTION	119
CLINICAL EFFICACY AND RESEARCH	121
INTEGRATING AYURVEDA WITH MODERN THERAPEUTICS	123
CHALLENGES AND LIMITATIONS	124
FUTURE DIRECTIONS	127
CONCLUSION	129
ACKNOWLEDGEMENTS	130
REFERENCES	130
 CHAPTER 7 IN VITRO AND IN VIVO PHARMACOLOGICAL SCREENING METHODS AVAILABLE FOR ALZHEIMER'S DISEASE AND DEMENTIA	134
<i>Smita Jain, Komal Kriti and Reetuparna Acharya</i>	
INTRODUCTION	135
2D <i>in vitro</i> Models	141
3D <i>in vitro</i> Models	144
Microfluidics-Based <i>in vitro</i> Models	147
CONCLUSION	153
DECLARATION ON THE USE OF AI	153
REFERENCES	153

CHAPTER 8 HERB-DRUG AND FOOD-DRUG INTERACTION IN THE TREATMENT OF ALZHEIMER'S AND DEMENTIA	160
<i>Reetuparna Acharya, Smita Jain and Komal Kriti</i>	
INTRODUCTION	161
DRUG-HERB INTERACTION	161
Mechanism of Drug-Herb Interaction	162
Ayurveda, in Identifying Effective Therapeutic Interventions for Neurogenerative Disorders	
Like Ad and Dementia	163
Phytochemicals and Ethnomedicinal Application of Various Plants Along With Their Bioactive Compounds.	165
Effect of Herbs on Hormones in the Management of Alzheimer Disease and Dementia	168
DIET WITH ALZHEIMER'S DISEASE AND DEMENTIA	169
Lipids: Cholesterol, Triglycerides & Fatty Acids	169
Carbohydrates: Mono and Polysaccharides	170
Trace Micromolecules: Vitamins and Minerals	171
The Microbiota Interaction	172
CONCLUSION: ALZHEIMER'S DISEASE, DRUGS, AND DIET	173
FUTURE PROSPECTIVE OF ALZHEIMER'S DISEASE AND DEMENTIA WITH HERBAL PRODUCT	174
DECLARATION ON THE USE OF AI	175
REFERENCES	175
CHAPTER 9 RESEARCH AND CLINICAL STUDIES OF BRAIN BOOSTING HERBS: THE ULTIMATE GUIDE TO USE HERBAL MEDICINE FOR DEMENTIA AND ALZHEIMER'S	178
<i>Saloni Yadav, Shraddha Mahajan, Sweta S. Koka and G.N. Darwhekar</i>	
INTRODUCTION	179
Overview of Alzheimer's & Dementia	180
Mechanism Behind Dementia	180
Conventional Treatment Approaches	182
Limitations of Conventional Treatments	182
Need, Purpose, and Scope of Therapy	182
BRAIN-BOOSTING HERBS IN THE TREATMENT OF ALZHEIMER'S AND DEMENTIA	182
Overview and Historical Use of Herbs in Treating Cognitive Decline	183
Popular Brain-Boosting Herbs	184
Mechanisms of Action	197
INTEGRATING HERBAL MEDICINE INTO CONVENTIONAL ALZHEIMER'S TREATMENT	201
Combining Herbal Remedies with Conventional Treatments	201
Risks and Benefits of Polypharmacy	202
Benefits	202
Risks	202
Potential Interactions with Prescription Drugs	203
Patient-Centered Approaches in Treatment Plans	204
FUTURE DIRECTIONS AND CONCLUSION	205
Promising Areas for Future Research	205
The Need for Rigorous Clinical Trials	207
Conclusion: The Role of Herbs in Modern Alzheimer's and Dementia Treatment	208
DECLARATION ON THE USE OF AI	208
REFERENCES	208

CHAPTER 10 FUTURE DIRECTIONS IN HERBAL MEDICINES AND NOOTROPICS AS COGNITIVE ENHANCERS	217
<i>Ravikant Gupta, Vaibhav Rajoriya, Sudha Vengurlekar and Sachin Kumar Jain</i>	
INTRODUCTION	217
Historical Perspective	219
Mechanisms of Action	223
Popular Herbal Medicines	224
Modern Nootropics	229
Comparative Analysis	230
Emerging Trends	232
Clinical Trials and Research	233
Potential Applications	234
Challenges and Future Directions	236
FUTURE RESEARCH OPPORTUNITIES	237
CONCLUSION	238
DECLARATION ON THE USE OF AI	239
REFERENCES	239
CHAPTER 11 CONCLUSION	242
<i>Komal Kriti, Reetuparna Acharya and Smita Jain</i>	
CHAPTER 1: INTRODUCTION TO MEMORY AND NEURODEGENERATIVE DISORDERS	242
Conclusion	242
Memory Formation has Three Phases	242
Neurodegenerative Disease Types and Characteristics	243
Several Neurodegenerative Disorders Impair Memory and Cognition	243
Neurodegenerative Disease Memory Dysfunction	244
Different Neurodegenerative Illnesses Affect Different Kinds of Memory	244
Manage Memory Impairment Interventions	245
Future Paths	245
CHAPTER 2: AN OVERVIEW OF DEMENTIA AND ALZHEIMER'S	245
Conclusion	245
Understanding Alzheimer's	245
Alzheimer's Stages	246
Key AD Pathology Features	246
CHAPTER 3: NOOTROPICS AND SMART DRUGS: AN OVERVIEW	247
Conclusion	247
CHAPTER 4: HERBAL DRUGS AND THEIR ACTIVE PHYTOCONSTITUENTS USED FOR THE TREATMENT OF ALZHEIMER'S AND DEMENTIA	249
Conclusion	249
CHAPTER 5: NON-HERBAL APPROACHES BEYOND MEDICATION: COMPLEMENTARY THERAPIES FOR ALZHEIMER'S AND DEMENTIA	250
Conclusion	250
CHAPTER 6: COGNITION-ENHANCING AYURVEDIC REMEDIES: A NATURAL STRATEGY AGAINST ALZHEIMER'S AND DEMENTIA	251
Conclusion	251
CHAPTER 7: <i>IN VITRO</i> AND <i>IN VIVO</i> PHARMACOLOGICAL SCREENING METHODS AVAILABLE FOR ALZHEIMER'S DISEASE AND DEMENTIA	253
Conclusion	253
CHAPTER 8: HERB-DRUG AND FOOD-DRUG INTERACTION IN THE TREATMENT OF ALZHEIMER'S AND DEMENTIA	255

Conclusion	255
CHAPTER 9: RESEARCH AND CLINICAL STUDIES OF BRAIN BOOSTING HERBS: THE ULTIMATE GUIDE TO USE HERBAL MEDICINE FOR DEMENTIA AND ALZHEIMER'S	257
Conclusion	257
CHAPTER 10: FUTURE DIRECTIONS IN HERBAL MEDICINES AND NOOTROPICS AS COGNITIVE ENHANCERS	259
Conclusion	259
DECLARATION ON THE USE OF AI	260
REFERENCES	260
SUBJECT INDEX	263

Foreword

The overarching goal of public health is to protect and improve the health of individuals, families, communities, and populations, locally and globally. In collaboration with physicians, nurses, and other healthcare professionals, pharmacists have an incredible opportunity and the skills to contribute toward this goal. In recent years, the role of public health education and training within the profession of pharmacy has been formalized for students and practicing pharmacists alike. Pharmacy curricula, as part of accreditation requirements, are required to design programs that achieve educational outcomes in population-based care, cultural sensitivity, interprofessional collaboration, and health and wellness.

In an effort to further these goals, the following casebook was developed. While a number of public health pharmacy educational texts are available, there is currently a paucity of resources that focus on the application of public health knowledge in a case-based format for pharmacists. Casebooks in health sciences allow opportunity for students to work toward educational competencies through patient-oriented scenarios prior to or in concert with formal clinical experiences.

The facts and numbers about Alzheimer's disease (AD) can be hard to fathom: over 5 million living with AD in the US alone, the 6th leading cause of death, a \$300 billion cost in 2020 that projects to \$1.1 trillion by 2050. To the 16 million caregivers of AD patients, however, the numbers become all too real and can be the challenge of their lives. The afflicted no longer recognize us, and we no longer recognize them. Familiar loved ones become strangers. Their utter dependence, coupled with our sense of duty, taints our fond memories with bitterness and resentment.

In many ways, AD is also the existential fight of our lives as human beings. The human brain is a pinnacle of evolutionary achievement, with the cognition it enables (i.e., its abilities to feel, think, and learn) being the highest expression of this evolution. Thus, AD cuts straight to the core of what it means to be human. As a society, why are not we closer to understanding AD and having a cure? Since the 1980s, the US government, through its National Institutes of Health (NIH), has developed an impressive network of AD research centers, now more than 30 strong, which includes a coordinating center (National Alzheimer's Coordinating Center) and consortia to combine patient data and get the best minds together to figure out the genetics (AD Genetics Consortium).

There is significant potential in discovering drugs based on plant extracts. Plants such as *Ginkgo biloba*, Ashwagandha, and Ginseng have beneficial effects on brain health and the nervous system, which may lead to improvements in memory and concentration, and a reduction in dementia symptoms.

Sanyam Gandhi
Senior Regulatory Lead Takeda
Pharmaceutical 500 Kendall St Cambridge
MA, USA

Preface

Alzheimer's disease and dementia have emerged as major global health challenges, affecting millions of individuals and their families. As these conditions continue to rise, conventional medical treatments often provide only symptomatic relief, leaving patients and caregivers searching for alternative solutions. Among the most promising areas of exploration is herbal medicine, which has been used for centuries across cultures to enhance cognitive function, improve memory, and slow neurological decline.

Brain Boosting Herbs: The Ultimate Guide for Using Herbal Medicine for Dementia and Alzheimer's aims to bridge the gap between traditional herbal wisdom and modern scientific research. This book provides an evidence-based approach to understanding how various herbs and natural compounds support brain health, focusing on their mechanisms, phytoconstituents, clinical efficacy, and safety.

This comprehensive book covers a wide spectrum of topics, including:

- The science behind Alzheimer's and dementia.
- Conventional and alternative treatments by exploring the limitations of pharmaceuticals and the role of herbs as complementary therapies.
- Herbal remedies and their active compounds that have shown neuroprotective benefits.
- Lifestyle modifications and complementary therapies are examined to determine the role of diet, exercise, and stress management in cognitive health.
- The future of herbal medicine for emerging research, clinical trials, and technological innovations in herbal drug development.

This book is designed for healthcare professionals, researchers, caregivers, and anyone interested in natural cognitive health solutions. By integrating traditional herbal practices with modern scientific insights, we hope to empower readers with the knowledge to make informed decisions in the pursuit of better brain health.

Sachin Kumar Jain
Oriental College of Pharmacy & Research
Oriental University, Indore
Madhya Pradesh, India

&

Kratika Daniel & Sudha Vengurlekar
Faculty of Pharmacy
Oriental University, Indore
Madhya Pradesh, India

List of Contributors

Arpit Sivchandan	Faculty of Pharmacy, Mandsaur University, Mandsaur, India
G.N. Darwhekar	Acropolis Institute of Pharmaceutical Education & Research, Indore, Madhya Pradesh, India
Kajal Mudgal	Faculty of Pharmacy, Mandsaur University, Mandsaur, India
Kapil Juvele	Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Mumbai, India
Kinjal P. Patel	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, India
Komal Kriti	Department of Pharmaceutical Sciences, Dhanbad College of Pharmacy, Dhanbad, Jharkhand, 826004, India Faculty of Pharmacy, Oriental University, Indore, 453555, Madhya Pradesh, India
Manasi M. Choudhari	Department of Quality Assurance, Shraddha Institute of Pharmacy, Washim, India
Monali N. Dumore	Department of Quality Assurance, Dadasaheb Balpande College of Pharmacy, Besa, Nagpur, India
Namita Hegde	Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Mumbai, India
Nitin G. Dumore	Department of Quality Assurance, Dadasaheb Balpande College of Pharmacy, Besa, Nagpur, India
Palmi Modi	Department of Pharmacy, L.J. University, Ahmedabad, Gujarat, India
Rajesh A. Maheshwari	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, India
Rajesh Hadia	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, India
Rahul Trivedi	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India
Ravikant Gupta	School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
Reetuparna Acharya	University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, 140413, India
Rupesh Soni	Faculty of Pharmacy, B.R. Nahata College of Pharmacy, Mandsaur University, Mandsaur, Madhya Pradesh, India
Sachin Kumar Jain	Faculty of Pharmacy, Oriental University, Indore, Madhya Pradesh, India
Sahana Ghosh	Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Mumbai, India
Saloni Yadav	Acropolis Institute of Pharmaceutical Education & Research, Indore, Madhya Pradesh, India

Shraddha Mahajan	Acropolis Institute of Pharmaceutical Education & Research, Indore, Madhya Pradesh, India
Shrikant Joshi	Department of Pharmaceutics, Maliba College of Pharmacy, UKA, Tarsadia University, Gujarat, India
Shweta Bhandari	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, India
Shweta Gandhi	Department of Pharmacy, L.J. University, Ahmedabad, Gujarat, India
Smita Jain	Department of Pharmacology, School of Pharmacy & Technology Management, SVKM's NMIMS Deemed to be University, Shirpur, Maharashtra, India
Sudha Vengurlekar	Faculty of Pharmacy, Oriental University, Indore, Madhya Pradesh, India
Swapnil Goyal	Faculty of Pharmacy, Mandsaur University, Mandsaur, India
Swati Deshmukh	Department of Quality Assurance, Shraddha Institute of Pharmacy, Washim, India
Sweta S. Koka	Acropolis Institute of Pharmaceutical Education & Research, Indore, Madhya Pradesh, India
Vaibhav Rajoriya	Vedic Institute of Pharmaceutical Education and Research, Sagar, Madhya Pradesh, India

CHAPTER 1

Introduction to Memory and Neurodegenerative Disorders

Sahana Ghosh¹, Kapil Juvele¹ and Namita Hegde^{1,*}

¹ *Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Mumbai, India*

Abstract: The current chapter presents a wide-ranging view of memory as one of the fundamental cognitive functions, with attention to its neurobiological substratum and the effect of neurodegenerative diseases on memory processes. Memory is one of the many cognitive functions that enable learning, skill acquisition, storage, and recollection of information. Memory is a complex interplay of encoding, storage, and retrieval mediated by many neurotransmitters in many brain regions, including the hippocampus and amygdala. Furthermore, the synaptic plasticity responsible for memory formation is considered to elucidate how it is disrupted in neurodegenerative diseases. Slow but progressive neuronal degeneration is a characteristic of neurodegenerative diseases. Neurodegenerative diseases often result in cognitive decline, especially in short- and long-term memory. Several pathological conditions disrupt intricate synaptic processes and alter the balance of events, thereby influencing memory functions. The chapter highlights protein misfolding, neuro-inflammation, and oxidative stress as underlying mechanisms of memory impairment, emphasizing the worth of this understanding for therapeutic modalities.

Keywords: Atrophy, Brain regions, Cerebellum, Cognition, Impairment.

INTRODUCTION

Memory is a cognitive function that enables an individual's learning, skill acquisition, storage, and recollection of information. Memory plays a vital role in day-to-day activities and influences every aspect of daily life. Memory also plays a profound role in maintaining overall health and defines human existence. The vital role of memory in an individual's life could be understood from a neurobiological perspective, where memory is a highly complex and dynamic neurochemical event characterized by a continuous dynamic biochemical interaction among neurons, synapses, and neurotransmitters [1].

* **Corresponding author Namita Hegde:** Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Mumbai, India; E-mail: namita.hegde@nmims.edu

Memory formation is thought to occur predominantly due to the plasticity of synapses, which is the synaptic ability to strengthen or weaken the connections between neurons through adaptive changes induced by the increased or decreased levels of their activity [2]. Modulation of synaptic strength is greatly influenced by neurotransmitters like acetylcholine, dopamine, and glutamate, which perform an essential task in neuronal communication. Besides neurotransmitters, many brain regions have specific functions in neural activity, memory formation, and recall [3]. For example, the hippocampus processes long-term memory. Emotional memory, such as feelings of fear or pleasure, is created by the amygdala.

However, several pathological conditions disrupt the intricate synaptic processes and change the balance of events, thus influencing memory functions. The synaptic disturbances predominantly arise from alterations of neurotransmitter-mediated neuronal communication, structural damage to neurons, and compromised Central Nervous System (CNS) functions linked to hyperactivity, aggregation of misfolded proteins, neuro-inflammation, oxidative stress, or neurotransmitter imbalance [4]. Several neurodegenerative diseases are the chief pathological conditions that disrupt memory functions. Slow degeneration of neural tissues is manifested by progressive aggregation of misfolded proteins and synaptic dysfunction, with a diminishment of synapse integrity. All these processes collectively affect the memory functions. Genetic risk factors, inflammatory responses, and oxidative stress amplify the damage to memory-related processes [5].

Perhaps one of the most critical questions in modern neuroscience research is understanding how memories are made or lost. The current book chapter provides clear insights into behavior and memory, which can inform the development of new therapeutic strategies.

NEUROSCIENCE OF MEMORY

Understanding the fundamental neuroscience of memory is important for understanding how neurodegenerative diseases affect memory. Memory can be categorized into several types, with distinct mechanisms, duration, and capacities. Memory refers to the complex actions of encoding, storing, and retrieving information. Encoding denotes the initial processing of information stored in various areas of the brain, particularly the hippocampus, which consolidates short-term memories into long-term ones. Retrieval includes those contexts or cues that trigger the reactivation of networks in the prefrontal cortex and other cortical regions [6]. Neuroimaging studies have shown that memory consists of a network of regions closely involving the hippocampus, medial temporal lobes, prefrontal cortex, and other cortical and subcortical areas [7].

Types of Memory

Memory is a complex and essential cognitive function that enables humans to encode, store, and retrieve information. Researchers tend to categorize memory into types based on various characteristics, including duration, capacity, and the nature of information stored. The main types of memory include sensory, short-term, and long-term [8].

Sensory memory is the very first stage of memory in which sensory information is stored for a very short time, usually less than a second. Sensory information includes activities related to sight, sound, touch, taste, and smell. It acts as a buffer for stimulation coming from the sense organs before activating in-depth processing of the pertinent stimuli by the brain.

Short-term or working memory is associated with retaining small amounts of information for a limited time (up to 20-30 seconds). This memory is very important in problem-solving and reasoning. Usually, working memory maintains about four units of information simultaneously, but chunking can be used to increase this capacity. Chunking enables the breaking down of large amounts of information into smaller units to make it manageable.

Long-term memory stores information for long periods, such as years or even a lifetime. Long-term memory includes episodic, semantic, and procedural memories. Episodic memory includes a free personal experience, such as remembering an anniversary date. Semantic memory includes knowledge of facts and generalities about the world, such as knowing some historical dates. Procedural memory includes skills and tasks like bike riding or typing, learned through practice. Long-term memory has a vast storage capacity and great longevity, enabling individuals to retain much information over long periods [9].

Neurodegenerative diseases are characterized by slow but progressive degeneration of neurons. Neurodegenerative diseases often result in a decline in cognition, especially for several types of memory [10].

Process of Memory Formation

The process of memory formation comes in three steps: encoding, storage, and retrieval, as described in Fig. (1). Encoding transforms sensory information into a memory trace appropriate for representation in the brain. Encoding includes the processing of various sensory inputs to acquire information. Attention is needed to ensure successful encoding, subject to factors such as motivation, emotion, and meaning attached to the material.

CHAPTER 2

An Overview of Dementia and Alzheimer's

**Rahul Trivedi^{1,*}, Rajesh A. Maheshwari¹, Kinjal P. Patel¹, Shweta Bhandari¹,
Rajesh Hadia¹, Swapnil Goyal² and Rupesh Soni²**

¹ Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, India

² Faculty of Pharmacy, B.R. Nahata College of Pharmacy, Mandsaur University, Mandsaur, Madhya Pradesh, India

Abstract: Alzheimer's Disease (AD) is a highly concerning condition for those affected and their caregivers globally, posing a significant socioeconomic burden. The term dementia refers to a group of diverse diseases whose underlying causes and mechanisms are not yet fully understood. AD is the most prevalent type of dementia globally, making up about sixty percent of all dementia cases. The initial stage is characterized by short-term memory loss, such as difficulty recalling recent conversations, names, or events, along with apathy and depression. As the disease progresses, symptoms include disorientation in time and place, confusion, difficulty with communication, problems with personal hygiene, loss of speech and movement, and challenges with swallowing. AD is manifested by the assembly of beta-amyloid protein fragments in plaques outside the brain neurons and the formation of twisted strands of tau protein as tangles internal to the neurons. Other factors linked to Alzheimer's disease include chronic inflammation of neurons, reduced levels of acetylcholine, imbalanced metal ion levels, and oxidative stress in the brain. As for pharmacological treatments, the limited anti-AD therapies currently available are unable to avert the inception or slow the development of the disease. Although they offer only modest benefits, these treatments are still valuable as they help alleviate symptoms, slow clinical progression, and delay disability. These medications also come with a range of side effects, which can impact patient compliance. As a result, there is an urgent need to develop alternative therapies to address the onset and progression of AD.

Keywords: Alzheimer's disease, Beta-amyloid, Dementia, Excitotoxicity, Neurodegeneration, Neuroinflammation, Reactive oxygen species, Tau protein.

INTRODUCTION

The brain is often regarded as the most complicated structure in the human body. It comprises neurons and neuroglia, with neurons playing a key role in transmit-

* Corresponding author **Rahul Trivedi:** Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujarat, India; E-mail: trivrahul@gmail.com

ting and receiving nerve signals or impulses. Neurons are responsible for transmitting and receiving nerve impulses or signals. Microglia and astrocytes play a crucial role in supporting neuron function, quickly stepping in to aid when neurons experience injury or stress. As guardians of neuronal health, disruptions in microglial or astrocytic function can have profound effects on overall brain function. Neurons emit signals to inform neuroglia of their condition when they suffer from acute injury. Based on the severity of neuronal damage, neuroglia respond in two ways: they either support the recovery and regeneration of injured neurons or eliminate those considered nonviable. These neuroglial retorts are watched as typical neuroprotective and physiological mechanisms. Conversely, certain chronic processes lead to persistent neuroglial activation, ultimately impairing their physiological capacity to maintain homeostasis. This can result in harmful effects, potentially causing spectator damage due to neuroglial dysfunction [1, 2].

Degeneration of neurons occurs in both neuropathological conditions and the natural aging process of the brain. It is acknowledged that brain disorders, including cerebrovascular incidents and neurodegenerative diseases, are the leading causes of death worldwide. Neurodegenerative disease is categorized as a progressive medical condition that causes the gradual deterioration and death of neurons in the peripheral or Central Nervous System (CNS), clinically presenting as irreversible cognitive decline and/or movement disorders. Neurodegenerative diseases are incurable because most neurons do not regenerate when they are damaged [1, 3].

Dementia is a wide term that includes a number of progressive disorders that affect behaviour, memory, and cognitive abilities, making it extremely difficult for a person to do daily tasks. More than 65% of dementia cases are Alzheimer's Disease (AD), making it the most common kind. Currently, AD affects over five million individuals, with projections estimating more than 13 million cases by 2050. As per the report of the World Health Organization (WHO), in 2015, dementia impacted 47 million people globally, a number projected to rise to 75 million by the year 2030 and 132 million by the year 2050 [4, 5].

RISK FACTORS OF DEMENTIA

Factors that raise the likelihood of developing dementia include [3]:

Advancing age (more prevalent in individuals aged 65 and older)

- Depression
- Excessive alcohol consumption
- Elevated blood sugar levels (diabetes)

- Increased blood pressure (hypertension)
- Overweight or obesity
- Physical inactivity
- Smoking
- Social isolation

SIGN AND SYMPTOMS

The symptoms differ according to the stage of disease, like the primary stage, middle stage, and later stage.

Primary Stage

This phase is often overlooked because symptoms develop gradually. The signs are memory lapses, losing sense of time, and frequently becoming disoriented or lost.

Middle Stage

At this stage, the symptoms become more evident, such as forgetting names of people, obvious confusion, difficulty with communication, need for help with personal care, and repeatedly asking the same question.

Later Stage

At this point, individuals become fully reliant on caregivers. Memory is significantly impaired, including difficulty recognizing family and friends, loss of the ability to care for oneself, difficulty walking, and loss of track of time [5, 6].

TYPES OF DEMENTIA

According to the National Institutes of Health, various forms of dementia are categorized as described in Fig. (1) [6, 7].

- **AD** is characterized by the accumulation of beta-amyloid and tau proteins in the brain, which interfere with normal cognitive functions. This typically presents as memory disturbances, mood disturbances, thinking difficulties, inability to exercise judgment, behavioural disturbances, and emotional disturbances, eventually affecting physical control over the body.
- **Vascular Dementia:** Another most common form, arises when the brain is deprived of essential nutrients and oxygen due to disrupted blood flow. It can develop after a single stroke in a critical area of the brain or as a result of multiple small strokes. Additional contributing factors include heart attack history, irregular or speedy heartbeat, toughened arteries, constrictive blood

CHAPTER 3

Nootropics and Smart Drugs: An Overview

Vaibhav Rajoriya^{1,*}, Ravikant Gupta², Sudha Vengurlekar³ and Sachin Kumar Jain³

¹ *Vedic Institute of Pharmaceutical Education and Research, Sagar, Madhya Pradesh, India*

² *School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India*

³ *Faculty of Pharmacy, Oriental University, Indore, Madhya Pradesh, India*

Abstract: Nootropics, referred to as smart drugs, are a broad class of pharmaceuticals that enhance human cognition, memory, and learning, particularly when these processes are compromised. Nootropics include herbal formulations, synthetic compounds, and a few prescription medications, which act through various neurotransmitters and have neuroprotective properties. Nootropics are also effective in neurodegenerative disorders such as Alzheimer's and dementia. The chapter presents their classification, types, mechanisms of action, benefits, risks and side effects, their effective role, especially in Alzheimer's and dementia, along with case studies, clinical trials showing the integration of nootropics into therapeutic and industries to improve therapeutic outcomes and patient compliance.

Keywords: Alzheimer's, Cognition, Dementia, Memory, Nootropics, Smart Drugs.

INTRODUCTION

Nootropics are a diverse class of substances, sometimes referred to as smart drugs in English-language literature. Cornelius E. Giurgea coined the word nootropic in 1972–1973 to refer to drugs that mainly stimulate cognitive processes like memory and learning, particularly when these processes are compromised. In a way, they disrupt the Central Nervous System (CNS) neuronal cells' metabolism. The Greek words *noos*, which means to think, and *tropein*, which means to lead, make up the name [1].

* **Corresponding author Vaibhav Rajoriya:** Vedic Institute of Pharmaceutical Education and Research, Sagar, Madhya Pradesh, India; Email: rajoriyavaibhav@gmail.com

Classification

The three main types of nootropics are natural, synthetic, and dietary, and they offer possible advantages for cognitive health.

- **Natural Nootropics:** *Rhodiola rosea*, *Panax ginseng*, *Bacopa Monnieri*, *Centella asiatica*, and *Ginkgo biloba* are natural nootropics used in various traditional medicine systems, *e.g.*, Indian and Chinese [2]. *Ginkgo biloba* extract has specific neuroprotective effects that may be helpful in treating chronic cerebral hypoperfusion, according to an *ex vivo* rat study. The cholinergic system and inflammatory mediators were modulated by the extract's pharmacological action. They improve mental health, memory, mood, and cognitive clarity.
- **Synthetic Nootropics:** Noopept, Modafinil, Pyritinol, and Piracetam are synthetic nootropics and are used to improve learning, sleep disorders, and neuroprotection. The chemical name for piracetam is 2-(2-oxopyrrolidin 1-yl)acetamide. It is a cyclic derivative of acetamide and gamma-aminobutyric acid (GABA). It is believed that piracetam affects brain neurotransmission *via* modifying ion channels (Ca^{2+} and K^{+}), which results in a generalized increase in neuronal excitability. Piracetam was discovered by Corneliu E Giurgea [3].
- **Dietary Nootropics:** Omega-3 fatty acids, caffeine, and L-theanine are examples of dietary nootropics agents and are essential for brain structure and function, focus, alertness, and balanced cognitive activity [4].

TYPES OF NOOTROPICS

Nootropics can be classified into numerous types based on their origin and mode of action.

Natural Nootropics

Natural nootropics are utilized in various traditional medicine systems, *i.e.*, Chinese & Indian, and are valued to improve mental health and support cognition. *Ginkgo biloba* used in Chinese medicine, improves memory and cognitive function. *Panax Ginseng* improves mental health, cognition, and mental clarity. *Bacopa monnieri*, used in the Ayurvedic medicine system, improves focus, memory, and recall function of the brain [5].

Synthetic Nootropics

Piracetam, Modafinil, Noopept, aniracetam, and oxiracetam are a few examples of the synthetic nootropics. The synthetic nootropics are also used to improve memory, cognitive behaviors, and sleep disorders, enhance focus and alertness, and improve learning capacity and neuroprotection [6].

An Overview Dietary Nootropics

Dietary nootropics are used for daily life and improve brain and cognitive performance. Omega-3 fatty acids are dietary nootropics obtained from fish oil, used to support cognitive function. Caffeine extracted from Coffee and tea improves alertness and focus. L-theanine combined with caffeine promotes relaxation, calm, and balanced cognitive performance. Creatine is also a dietary nootropics agent, widely used by athletes to improve physical performance, short-term memory, and mental health [7].

Prescription Nootropics

Adderall, amphetamine, dextroamphetamine, methylphenidate, and donepezil are examples of prescription nootropic agents. These agents are prescribed for the management of Attention-Deficit/ Hyperactivity Disorder (ADHD). These agents work on the dopaminergic and non-adrenergic neurotransmitters to improve cognitive behaviors, focus, relaxation, maintain mental ability and sustain attention control. Donepezil is used in the treatment of Alzheimer's to improve memory and learning by enhancing cholinergic signaling in cortical and hippocampal regions [8].

Over-the-Counter (OTC) Nootropics

Huperzine A and Choline are OTC nootropics used to improve memory function and alertness. Huperzine A, is an alkaloid extracted from *Huperzia serrata* moss, and it improves memory, mental health, and alertness by acetylcholinesterase inhibition, increasing the concentration of acetylcholine in the brain. Ginkgo biloba leaf extract is also used as an OTC nootropics and improves antioxidant properties, memory, attention, and cognitive health. Choline is also used for brain health and as a precursor of acetylcholine, improving memory, focus, cognitive function, and maintaining the structural integrity of the cell membrane. Dietary sources include eggs, meat, and certain vegetables incorporated into nutritional supplements, which also improve cognitive performance [9].

Herbal Nootropics

Withania Somnifera (Ashwagandha), *Gotu Kola* (*Centella Asiatica*), and *Lion Man Mushroom* (*Hericium Erinaceus*) are a few examples of herbal nootropics. These plant-derived compounds improve cognitive performance, memory, and attention, reduce stress, and have neuroprotective, antioxidant properties. These agents also play a critical role in neurological survival and regeneration of neurons and, as natural agents, improve memory and maintain brain function [10].

CHAPTER 4

Herbal Drugs and their Active Phytoconstituents used for the Treatment of Alzheimer's and Dementia

Sachin K. Jain¹, Rahul Trivedi², Swapnil Goyal^{3,*}, Arpit Sivchandan³, Kajal Mudgal³, Palmi Modi⁴ and Shweta Gandhi⁴

¹ Faculty of Pharmacy, Oriental University, Indore, Madhya Pradesh, India

² Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India

³ Faculty of Pharmacy, Mandsaur University, Mandsaur, India

⁴ Department of Pharmacy, L.J. University, Ahmedabad, Gujarat, India

Abstract: As the global populace continues to age, neurodegenerative diseases, which manifest in the regular harm to neurons in specific sections of the nervous system, are becoming more common. These disorders have similar underlying mechanisms and characteristics, such as aberrant protein aggregation, mitochondrial dysfunction, oxidative stress, and inflammation, despite their diverse clinical manifestations. The most common cause of dementia, accounting for 60–80% of cases, is Alzheimer's Disease (AD). The prevalence of dementia is rising at a startling rate as the world's population ages. Dementia is more common in older adults, but it can also strike children who are overweight. Regular consumption of phytochemicals has been linked to improved mental and physical function, increased neuronal cell survival, and strengthened antioxidant defenses in the body, according to numerous studies. Researchers are paying more attention to the possible neuroprotective benefits of plant-derived chemicals present in food and agrifood by-products, as there are still no effective treatments for neurodegenerative illnesses. Phytochemicals are of special interest to researchers since many of them have excellent medicinal potential and little negative effects. Because of their anti-inflammatory, antioxidant, and anticholinesterase qualities, phytochemicals are being investigated as potential treatments for neurodegenerative illnesses. For both natural and synthetic medications to effectively treat brain problems, they must be able to pass through the Blood-Brain Barrier (BBB). This study examines a number of studies on phytochemicals and their potential for treating neurodegenerative diseases, emphasizing how they can have a variety of therapeutic effects.

* **Corresponding author Swapnil Goyal:** Faculty of Pharmacy, Mandsaur University, Mandsaur, India; Tel: 9907860790; E-mail: swapnilmip@gmail.com

Keywords: Alzheimer's and Dementia, Acetylcholinesterase (AChE), Amyloid-beta ($A\beta$), Herbal Drugs, Nitric oxide (NO), Non-enzymatic antioxidants, NF- κ B levels, Neuroinflammation, Phytoconstituents, Reactive Oxygen Species (ROS).

INTRODUCTION

Globally, neurodegenerative illnesses are becoming a bigger problem. A consensus reached using the Delphi approach states that Alzheimer's Disease (AD) is on the rise, affecting an estimated 26.6 million individuals globally. By 2050, this figure is expected to increase to 106.2 million. Approximately 6.3 million people worldwide suffer from Parkinson's Disease (PD), with 1.2 million instances occurring in Europe [1]. In Europe, there are 4 to 8 cases of Huntington's Disease (HD) for every 100,000 people, but in the US, there are roughly 2 to 7 cases of ALS for every 100,000 people. Increased oxidative and nitrosative stress, mitochondrial dysfunction, protein misfolding and aggregation, synapse loss, and decreased neuronal survival are among the common clinical characteristics of these illnesses at different stages [2, 3]. When immune cells and neurones come into contact with harmful proteins, they need a lot of energy to fight off the oxidative and nitrogenous stress that results, which causes mitochondrial dysfunction. Cytochrome C and other mitochondrial proteins are released as a result of this failure, which aids in apoptosis. Excessive protein aggregation impairs neuronal function and cellular signaling, which ultimately leads to neuronal death. A decline in cognitive ability that interferes with day-to-day activities is referred to as dementia. It is a syndrome linked to a number of neurological conditions rather than a specific illness. Around 60-80% cases of dementia are caused by Alzheimer's Disease (AD), making it the most prevalent among them. Specifically, older persons are more affected by this progressive neurological condition known as AD. The generation of abnormal proteins in the brain, such as tau tangles and amyloid-beta plaques, underlies loss of memory, decline in cognitive function, and behavioral abnormalities [4 - 6]. Alzheimer's disease is thought to be caused by a confluence of lifestyle, environmental, and genetic factors, while the precise etiology is yet unknown. Cognitive decline and gradual dementia are hallmarks of Alzheimer's Disease (AD), a chronic neurodegenerative illness. The number of people with dementia is increasing quickly as the world's population ages. Although dementia primarily affects the elderly, children who are overweight may also develop dementia [7, 8].

For AD, there is currently no proven cure. Recent research, however, has offered strong evidence that phytochemicals and botanicals may help postpone the start of AD. It has been demonstrated that consistent use of these drugs, particularly in the early stages of the disease, slows its progression. Regular consumption of phytochemicals has been shown in numerous studies to boost antioxidant defense,

increase neuronal cell survival, and improve mental and physical performance [9, 10]. The activation of the antioxidant system including nuclear factor (erythroid-derived 2)-like 2 (Nrf2), sirtuin, and forkhead box O (FOXO) transcription factors, chaperones, neurotrophic factors, and the inhibition of acetylcholinesterase (AChE) activity, are some of the factors that affect neurodegenerative diseases. The use of specific plant compounds and phytochemicals to treat incurable illnesses such as neurodegenerative diseases has also been supported by additional research. Compared to manufactured medications, natural phytochemicals are frequently thought to be less harmful. However, the medical efficacy, repeatability, mechanisms of action, and identification of active constituents of traditional herbal medicines—which are usually made from basic materials—are called into question [11 - 13]. Additionally, phytochemicals interact with neurotrophins (*e.g.*, NGF, BDNF, NT-3, and NT-5) and neuroinflammatory mediators. For instance, by encouraging the development of HIF-1 α and VEGF, maslinic acid, a possible nutraceutical triterpene, shields cells against Nitric Oxide (NO) and reactive oxygen species (ROS). Furthermore, Camellia sinensis extract-derived (–)-epigallocatechin-3-gallate has been demonstrated to lessen inflammation brought on by cytokines produced by methamphetamine. Dietary tocotrienols control the levels of phospholipase A2, COX-2, lipoxygenase, and NF- κ B, which helps prevent neuronal cell death. Alzheimer's disease is less common in India when curcuminoids are regularly consumed as part of the diet. By preventing cytokine generation and microglia activation in AD models, these substances may lessen inflammatory damage [14, 15]. ROS/RNS, which are implicated in cellular inflammation and the activation of macrophages and other inflammatory mediators, have been demonstrated to be suppressed by phytochemicals such as EGCG, curcumin, and resveratrol. These characteristics demonstrate how phytochemicals may be used as therapeutic targets for neurodegenerative illnesses.

PATHOPHYSIOLOGY AND CAUSES OF ALZHEIMER'S DISEASE

AD is primarily associated with the accumulation of amyloid-beta (A β) plaques and tau protein tangles in the brain. Recent studies have highlighted additional factors contributing to AD pathology [16]:

- **Metal Dyshomeostasis:** Imbalances in metals such as copper, iron, and zinc have been linked to A β aggregation and tau pathology, suggesting that metal homeostasis plays a role in AD progression.
- **Neuroinflammation:** In the brain regions, chronic inflammation, which is facilitated by activated microglia and astrocytes, has been implicated in

CHAPTER 5

Non-Herbal Approaches Beyond Medication: Complementary Therapies for Alzheimer's and Dementia

Monali N. Dumore^{1,*}, Manasi M. Choudhari², Nitin G. Dumore¹, Shrikant Joshi³ and Swati Deshmukh²

¹ Department of Quality Assurance, Dadasaheb Balpande College of Pharmacy, Besa, Nagpur, India

² Department of Quality Assurance, Shraddha Institute of Pharmacy, Washim, India

³ Department of Pharmaceutics, Maliba College of Pharmacy, UKA, Tarsadia University, Gujarat, India

Abstract: Dementia and Alzheimer's disease seriously impair social, emotional, and cognitive functioning, creating health issues that go beyond the reach of traditional medical interventions. Despite being essential for symptom management, drugs often fail to meet the more comprehensive requirements of patients and their caregivers. With an emphasis on patient-centered, holistic treatment practices, this chapter examines non-herbal supplementary therapies as complementary to conventional methods. The first part of the chapter explains the fundamentals of complementary treatments and how they might improve the general quality of life for those suffering from dementia. It emphasizes reminiscence-based activities, systematic physical exercise regimens, cognitive stimulation treatment, and creative therapies like music and art. The potential of these techniques to maintain cognitive function, enhance emotional health, and encourage social connection is investigated. The efficacy of sensory-based techniques in promoting relaxation and lowering anxiety is being investigated, including aromatherapy, tactile treatment, and light therapy. New developments that have the potential to improve the lives of people with dementia and Alzheimer's disease include mindfulness exercises, animal-assisted therapies, and virtual reality apps. These innovative methods are assessed for their capacity to improve communication, reduce behavioral disruptions, and provide happy and engaging moments. To optimize their impact, the chapter highlights the importance of tailoring these interventions to each person's specific preferences, cultural background, and life experiences. The chapter also emphasizes the value of complementary treatments in assisting caregivers, whose health is essential to providing care in a sustainable manner. In order to improve caregiver resilience and promote a cooperative

* Corresponding author Monali N. Dumore: Department of Quality Assurance, Dadasaheb Balpande College of Pharmacy, Besa, Nagpur, India; E-mail: nitingdumore@gmail.com

caring environment, strategies for stress management, education, and shared therapeutic activities are offered.

This chapter promotes a holistic approach to dementia care that incorporates evidence-based non-herbal therapies and pharmaceutical treatments by fusing clinical research with real-world applications. The objective is to enable healthcare professionals, caregivers, and legislators to use cutting-edge, non-invasive approaches that cater to the complex requirements of individuals impacted by dementia and Alzheimer's disease, guaranteeing a more humane and respectable care experience.

Keywords: Alzheimer's disease, Cognitive stimulation, Complementary therapies, Dementia care, Non-herbal treatments.

INTRODUCTION

Overview of Alzheimer's Disease

The primary cause of dementia in older persons is Alzheimer's Disease (AD), a chronic, progressive neurological illness. It progressively reduces everyday functioning and independence by affecting cognitive areas, including memory, thinking, and judgment. The formation of amyloid-beta ($A\beta$) plaques between neurons and neurofibrillary tangles made of hyperphosphorylated tau protein inside neurons are two of AD's defining pathogenic hallmarks. These anomalies cause brain atrophy, interfere with synaptic connections, and lead to neuronal death, especially in areas such as the hippocampus involved in learning and memory [1]. Advanced age is the main risk factor for AD, although other risk factors include head trauma, cardiovascular illness, low cognitive engagement throughout life, and genetic susceptibility, particularly the existence of the APOE $\epsilon 4$ allele. Clinical symptoms usually start off as minor confusion and memory loss and escalate to language problems, disorientation, and behavioral abnormalities. Cholinesterase inhibitors (donepezil, rivastigmine) and NMDA receptor antagonists (memantine) are examples of pharmacological therapy that may alleviate symptoms and somewhat impede the course of the illness. Alzheimer's disease presently has no known cure, despite continuous research, quality of life can only be improved by early identification and supportive treatment [2].

Overview of Dementia

The word “dementia” refers to a group of clinical illnesses that are defined by a gradual loss of cognitive function that is severe enough to interfere with social and everyday functioning. It includes a variety of causes, the most common being Alzheimer's disease, which is followed by frontotemporal dementia, Lewy body dementia, and vascular dementia. Different neuropathological causes are linked to each type: Lewy body dementia includes aberrant alpha-synuclein deposits,

vascular dementia is caused by decreased cerebral blood flow, and frontotemporal dementia is caused by degeneration of the frontal and temporal lobes [3]. Aging, genetic predisposition, and changeable lifestyle factors, including smoking, sedentary behavior, and poor cardiovascular health, are risk factors for dementia. To determine the underlying reason, a diagnosis usually includes clinical examination, neuroimaging, and cognitive tests. Despite the fact that dementia cannot be cured, treatment techniques aim to improve patient well-being, reduce behavioral symptoms, and decrease cognitive loss. Pharmacological treatments (such as cholinesterase inhibitors), cognitive training, and lifestyle changes incorporating mental and physical stimulation are examples of therapeutic strategies. Better long-term results and prompt action are made possible by early detection [4].

Limitation for Conventional Treatment

- **Limited Effectiveness in Symptom Management**

By raising acetylcholine levels in the brain, cholinesterase inhibitors may momentarily enhance memory and cognitive abilities in some people. These effects, however, are usually mild and transient, lasting only a few months to a year, and have no discernible impact on the disease's long-term course. These drugs become less effective in later stages of Alzheimer's disease due to the ongoing loss of brain cells and the buildup of tau tangles and amyloid plaques. By lowering excitotoxicity, memantine, which controls glutamate activity, may help treat moderate to severe Alzheimer's disease; however, it only slightly alleviates symptoms and ignores the underlying causes of the illness.

- **Inability to Cure or Stop Disease Progression**

The fact that traditional therapies do not change the fundamental causes of dementia may be the biggest drawback. The pathogenic accumulation of amyloid plaques, neurofibrillary tangles, and neurodegeneration, which are characteristics of Alzheimer's disease, are not addressed by these drugs. Because of this, even while they could temporarily alleviate symptoms, they do not stop future cognitive deterioration or delay the disease's course. As a result, despite therapy, patients and caregivers must deal with the unavoidable progression of symptoms [5].

- **Side Effects and Tolerability Issues**

Memantine and cholinesterase inhibitors are often linked to adverse effects, including weariness, sleeplessness, dizziness, and gastrointestinal discomfort

CHAPTER 6

Cognition-Enhancing Ayurvedic Remedies: A Natural Strategy Against Alzheimer's and Dementia

Vaibhav Rajoriya^{1,*}, Ravikant Gupta², Sudha Vengurlekar³ and Sachin Kumar Jain³

¹ Vedic Institute of Pharmaceutical Education and Research, Sagar, Madhya Pradesh, India

² School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India

³ Faculty of Pharmacy, Oriental University, Indore, Madhya Pradesh, India

Abstract: Ayurvedic medicine, with its rich history and holistic approach, offers a range of herbal preparations known for their cognitive-enhancing properties. These traditional remedies, rooted in ancient wisdom, have shown potential in supporting brain health and improving cognitive function, particularly in the context of neurodegenerative conditions such as Alzheimer's disease and dementia. This chapter provides an in-depth exploration of Ayurvedic preparations and their role as cognition enhancers, particularly in the context of Alzheimer's disease and dementia. This chapter explores Ayurvedic formulations, their mechanisms, and their integration with modern therapeutic strategies to provide a comprehensive approach to cognitive health. The chapter delves into the active compounds found in these herbs, their mechanisms of action, and clinical efficacy. It also examines the integration of Ayurvedic practices with modern therapeutic strategies to provide a comprehensive approach to cognitive health. By understanding these traditional remedies and their scientific basis, this chapter aims to highlight the potential benefits of Ayurveda in managing and improving cognitive function in neurodegenerative conditions.

Keywords: Alzheimer's disease, Ayurvedic medicine, Cognitive enhancers, Dementia, Herbal formulations, Holistic approach, Traditional remedies.

INTRODUCTION

• Overview of Ayurvedic Medicine

Ayurveda is an ancient system of medicine that originated in India more than 3,000 years ago. The name Ayurveda is derived from the Sanskrit words Ayur

* Corresponding author Vaibhav Rajoriya: Vedic Institute of Pharmaceutical Education and Research, Sagar, Madhya Pradesh, India; E-mail: rajoriyavaibhav@gmail.com

(life) and Veda (knowledge), meaning the science of life. It is often referred to as the mother of all healing [1].

Key Concepts of Ayurveda

- **Five Elements:** Ayurveda is based on the belief that the universe is made up of five elements: earth, water, fire, air, and ether [2]. These elements combine in the human body to form three fundamental energies known as doshas.
- **Doshas:** The three doshas—Vata, Pitta, and Kapha—are combinations of the five elements and are believed to govern all physiological and psychological processes in the body. Each person has a unique balance of these doshas, which determines their constitution or prakriti.
- **Vata:** Comprised of air and ether, Vata is associated with movement and governs bodily functions such as breathing, circulation, and digestion.
- **Pitta:** Made up of fire and water, Pitta is linked to metabolism and transformation, controlling digestion, energy production, and body temperature.
- **Kapha:** Consisting of earth and water, Kapha is related to structure and stability, regulating growth, immune function, and hydration.

Ayurvedic practitioners assess an individual's dosha balance and any imbalances that may be causing health issues. Treatments aim to restore balance through personalized approaches that may include: Procedures such as Panchakarma to cleanse and purify the body. Ayurveda emphasizes a holistic view of health, focusing on the mind, body, and spirit. It encourages harmony with nature and a balanced lifestyle to promote overall wellness. Ayurveda continues to be widely practiced in India and has gained popularity around the world as a complementary and alternative medicine. It is recognized for its emphasis on prevention, natural remedies, and personalized care [3].

• Importance of Cognitive Health

Herbs like Ginkgo biloba, turmeric, sage, and rosemary have been recognized for their potential in enhancing cognitive health and possibly slowing the progression of dementia and Alzheimer's disease [4]. Table 1 represents some ayurvedic herbs and their cognitive benefits. These herbs are rich in compounds with antioxidant and anti-inflammatory properties, which may help protect brain cells from damage and improve blood circulation to the brain. Including these herbs in your diet through teas, culinary dishes, or supplements could be a natural way to support brain health and boost memory function [5].

Table 1. Ayurvedic herbs and their cognitive benefits.

Herb	Botanical Name	Key Benefits	Mechanisms of Action
Brahmi	Bacopa monnieri	Enhances memory, reduces anxiety	Antioxidant, neuroprotective, neurotransmitter modulation
Ashwagandha	Withaniasomnifera	Improves cognition, reduces stress	Antioxidant, adaptogen, Neuroprotective
Shankhapushpi	Convolvulus pluricaulis	Enhances learning and memory	Neuroprotective, nootropic, Anxiolytic
Gotu Kola	Centella asiatica	Improves memory, reduces anxiety	Antioxidant, neuroprotective, enhances cerebral circulation
Shilajit	Asphaltum	Enhances memory, neuroprotective	Antioxidant, anti-inflammatory, mitochondrial support

AYURVEDIC CONCEPTS OF COGNITION

• Understanding the Mind in Ayurveda

In Ayurveda, the mind is considered a vital component of overall health and well-being, and its balance is essential for maintaining harmony in the body and spirit. The mind is influenced by the three gunas—Sattva, Rajas, and Tamas—which represent purity, activity, and inertia, respectively. Cultivating Sattva while balancing Rajas and Tamas is key to achieving mental clarity and stability. The mind's connection to the body is profound, with mental and emotional states directly impacting physical health and *vice versa*. Ayurveda also acknowledges the role of the three doshas—Vata, Pitta, and Kapha—in influencing mental states, with each dosha contributing unique characteristics to one's mental constitution. Practices such as meditation, yoga, herbal remedies, pranayama (breath control), and aromatherapy are employed to support mental health and restore balance. This holistic approach considers not just the mind and body, but also the individual's environment, relationships, and lifestyle, striving for overall harmony and well-being.

• Key Ayurvedic Principles for Cognitive Health

Ayurveda provides a rich framework for maintaining and enhancing cognitive health through natural and holistic practices [6]. Here are some key Ayurvedic principles for promoting cognitive well-being:

- **Balancing the Doshas:** In Ayurveda, cognitive health is closely linked to the balance of the three doshas—Vata, Pitta, and Kapha. An imbalance in any of

CHAPTER 7

***In vitro* and *In vivo* Pharmacological Screening Methods Available for Alzheimer's Disease and Dementia**

Smita Jain¹, Komal Kriti^{2,3} and Reetuparna Acharya^{4,*}

¹ Department of Pharmacology, School of Pharmacy & Technology Management, SVKM's NMIMS Deemed to be University, Shirpur, Maharashtra, India

² Department of Pharmaceutical Sciences, Dhanbad College of Pharmacy, Dhanbad, Jharkhand, 826004, India

³ Faculty of Pharmacy, Oriental University, Indore, 453555, Madhya Pradesh, India

⁴ University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, 140413, India

Abstract: Alzheimer's Disease (AD) is recognized as the most prevalent progressive neurodegenerative disorder leading to dementia. Given the diverse mechanisms involved in the pathogenesis of AD and dementia, researchers have developed various pharmacological screening models that enhance our understanding of the neurodegenerative processes underlying these diseases. These *in vitro* and *in vivo* screening modalities have been established through the induction of neurodegeneration by chemical agents, heavy metals, and endogenous substances, yielding promising results for the investigation of novel therapeutic strategies for managing AD and dementia. Despite these advances, the complex mechanisms of human disease progression are difficult to replicate precisely in these models. However, transgenic models have addressed some of these shortcomings. Chemicals such as scopolamine, streptozotocin, okadaic acid, and colchicine have been employed to induce neurodegeneration *via* oxidative stress and neuroinflammation. Additionally, heavy metals like aluminum, cadmium, and fluoride, along with endogenous substances such as amyloid- β 1-42 and acrolein, provide valuable insights into the induction of AD pathologies. Transgenic models that involve knock-in or knock-out of AD-associated genes, including APP23, PDAPP, APP/PS1, Tg2576, 5xFAD, and 3xTG, have proven to be effective murine models for studying AD pathogenesis. Recently reported AD models include the APP knock-in rat, the 28-kDa ChAT expression transgenic model, the oDGal mouse, and the oA β 25-35 model. Overall, this chapter aims to support the selection of appropriate models for drug design and development in the context of AD and dementia.

* **Corresponding author Reetuparna Acharya:** University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, 140413, India; Email: reetupharma25@gmail.com

Sachin Kumar Jain, Kratika Daniel, & Sudha Vengurlekar (Eds.)
All rights reserved-© 2026 Bentham Science Publishers

Keywords: Alzheimer's disease, Dementia, Neurodegeneration, Neuroinflammation, Transgenic mouse.

INTRODUCTION

Alzheimer's Disease (AD) is a complex, genetically heterogeneous disorder resulting in neurodegeneration and severe cognitive decline. The disease imposes a significant emotional and economic burden on individuals and is classified as the most common form of dementia, accounting for 60-80% of all cases. This debilitating condition affects roughly 50 million people worldwide and impacts the lives of family members and loved ones of approximately 10 million patients suffering from cognitive decline [1]. The Global Burden of Disease Study states that AD is recognized as the fastest-growing disorder among leading causes of death. Incidence rates indicate that about 10% of individuals aged 65 and above are affected by this condition [2]. AD is a progressive disease, clinically staged into four levels based on the severity of cognitive decline: Preclinical, mild, moderate, and severe. The preclinical phase involves no severe symptoms and is often overlooked. It features mild cognitive impairment, slight memory loss, and preservation of long-term memories. The disease begins with pathological impairments first in the entorhinal cortex, followed by the hippocampus. Individuals at this stage do not face difficulties in daily activities. As the disease progresses to the mild stage, cognitive symptoms become evident, with pathological changes in the cerebral cortex. Patients experience difficulty remembering new information, impaired problem-solving skills, and difficulty with appointments and executive functioning. Personality changes, loss of spontaneity, mood swings, confusion, and disorientation may also occur. In the moderate stage, further symptoms and pathological alterations appear in brain regions responsible for speech, language, sensory processing, and other functions. Patients may withdraw socially, exhibit behavioral issues, and display difficulties with visuo-spatial skills and language. Recognition of loved ones may become impaired. In the final, severe stage, patients lose independence for daily activities. Pathological damage affects all cortical areas, and cognitive abilities reach their lowest point. Symptoms include dyspraxia (inability to perform learned motor tasks), sleep disturbances, olfactory dysfunction, and extrapyramidal motor signs such as akathisia and dystonia [3]. The specific symptoms and severity vary among patients; however, post-mortem examinations of the central nervous system in individuals who succumbed to AD reveal neurofibrillary tangles, abnormal neuritic plaque accumulation, and synaptic loss [4]. Despite significant advances in understanding AD pathology and recent rapid developments, drugs designed to counteract AD-related pathology have often failed in clinical trials. These failures have prompted researchers to explore a broader array of pathological mechanisms underlying the disease. One approach is to conduct

functional studies using human-derived models and animals, which provide valuable insights into altered pathways and the development of targeted therapies [5].

- Overview of Alzheimer's disease and dementia and various pathogenic pathways associated with neurodegeneration

AD has been linked to progressive neurodegeneration that results from neuronal death in the hippocampal and parahippocampal regions of the brain, as well as from the abnormal aggregation of protein filaments or amyloidogenic proteins in affected areas. Extensive experimental, neuropathological, biochemical, and genetic research provides compelling evidence confirming that AD pathobiology varies significantly across different factors. Considering these factors, multiple mechanisms and hypotheses have been proposed. However, age remains the most critical risk factor. The amyloid cascade hypothesis suggests that amyloid β ($A\beta$), a 39-43 amino acid peptide, is derived from Amyloid Precursor Protein (APP) through the actions of β - and γ -secretase. Its deposition along with senile plaques in the brain appears as an early event and plays a major role in AD pathology [6]. Furthermore, the roles of several other proteins—such as PSEN1, PSEN2, APP, and APOE4—have been identified as modulators of $A\beta$ production and the formation of toxic senile plaques [7]. Additionally, abnormal hyperphosphorylation of tau protein leads to its accumulation into paired-helical filaments, which subsequently form Neurofibrillary Tangles (NFTs) [8]. Accordingly, there is sufficient evidence that $A\beta_{42}$ and tau proteins can serve as established cerebrospinal fluid biomarkers for AD. Although various mechanisms, such as the clearance of misfolded proteins, exist to protect the brain against AD, failure of these mechanisms can result in the condition's development. Diverse signaling pathways involving proteins like $A\beta$, ApoE, tau, GSK3 β , and PSEN1 are linked to neuronal cell survival and activity; however, dysfunction of these proteins and their associated signaling pathways has been observed in the etiology of AD.

Evidence from significant researchers has stated that AD is a multifactorial disease, and understanding the involvement and interconnection of various cell-signalling pathways in its pathogenesis is of paramount importance to identify novel druggable targets. Autophagy is a dynamic process triggered by stress stimuli and changes in environmental factors (such as nutrient starvation and pathogen infection); therefore, it has been correlated with various signalling pathways that play vital roles in the pathogenesis of AD [9]. Thus, the link between autophagy and other signalling mechanisms can be crucial in understanding neurodegeneration. Recent studies have contributed various

CHAPTER 8

Herb-Drug and Food-Drug Interaction in the Treatment of Alzheimer's and Dementia

Reetuparna Acharya¹, Smita Jain^{2,3} and Komal Kriti^{4,*}

¹ University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, 140413, India

² Department of Pharmacology, School of Pharmacy & Technology Management, SVKM's NMIMS Deemed to be University, Shirpur, Maharashtra, India

³ Department of Pharmaceutical Sciences, Dhanbad College of Pharmacy, Dhanbad, Jharkhand, 826004, India

⁴ Faculty of Pharmacy, Oriental University, Indore, 453555, Madhya Pradesh, India

Abstract: Alzheimer's Disease (AD) is a progressive disease that manifests in a variety of ways, including cognitive, functional, and behavioral symptoms that further lead to dementia. Pharmacotherapy plays a crucial role in treating these diseases. It is common for universal prescriptions to lead to pernicious clinical outcomes due to the resulting pharmacokinetic and pharmacodynamic associations. As a result, watchfulness is an essential component of spice drug co-medication. Herb-drug interactions, a clinical consequence of this practice, may jeopardize pharmacotherapy for neuropsychiatric disorders. Besides the time-honored potential of phytochemicals to inhibit and/or induce drug-metabolizing enzymes and transport proteins, numerous phytoconstituents are effective in exerting pharmacological effects on the central nervous system. These compounds comprise glycosides, flavonoids, tannins, polyphenols, triterpenes, sterols, and alkaloids, each exhibiting numerous pharmacological activities, including anti-inflammatory, anti-amyloidogenic, anticholinesterase, hypolipidemic, and antioxidant properties. This chapter highlights the phytochemistry and ethnomedicinal uses of numerous plants, along with their bioactive compounds. The pharmacological activities of medicinal herbs and their phytochemicals suggest potential actions against AD and dementia. These findings provide hope for addressing the challenges posed by these debilitating conditions.

Keywords: Alzheimer's Disease (AD), Complementary medicine, Dementia, Ethnomedicinal, Herb-drug interaction, Herb-food interaction, Phytoconstituents.

* **Corresponding author Komal Kriti:** Faculty of Pharmacy, Oriental University, Indore, 453555, Madhya Pradesh, India; Tel: +91-6204378250; E-mail: komal26kriti@gmail.com

INTRODUCTION

Before dealing with the topic of food and herb-drug interactions used to treat dementia and Alzheimer's Disease (AD), everyone must have a basic understanding of the condition. A neurodegenerative disease, Alzheimer's Disease (AD) is characterized by the gradual death of neurons, or brain cells. The brain's ability to function properly is compromised as neurons die, leading to a gradual deterioration of memory and other cognitive abilities. Consequently, at least two-thirds of all dementia cases that are identified are caused by Alzheimer's disease, making it the most prevalent cause of dementia [1]. Many individuals are already somewhat familiar with AD because it is becoming more and more common in today's world. The illness includes multiple phases and stages, each with unique difficulties for those who have been diagnosed, their families, and caretakers. One of the most effective strategies we have to combat Alzheimer's is education. The first step in understanding how to treat the disease effectively is being familiar with it. An extensive review of the usage of food-drug interactions and drug-herb interactions in the treatment of dementia and Alzheimer's disease will be given in this chapter. Using the most recent data, we describe the type of foods and herbs that should be consumed in addition to medications for the improvement of treatment of these two conditions with the fewest possible adverse effects. Once we have a basic understanding of AD, we will be better able to see the significance of using Ayurveda or phytochemicals in addition to medications. Also, we will understand much more clearly why our strategy of using food and herbal interactions to improve dementia and Alzheimer's disease treatment makes sense. Let's begin!

DRUG-HERB INTERACTION

As we know, herbs are obtained from natural sources, so they have fewer or no side effects. Plus, numerous preclinical and clinical studies show that many prescription medications interact with natural treatments. Polypharmacy is frequent since most individuals receiving treatment for Alzheimer's disease also have additional co-morbidities. These people have increased the risk of drug-herb interactions by supplementing their prescribed drugs with vitamins and herbs. The suppression or induction of activity exerted by a herb on a drug that is also provided is known as a drug-herb interaction. Drugs may also interact with food supplements, vitamins, and minerals in this way. The pharmacological or toxicological effects of either substance may be enhanced or diminished as a result of these interactions between herbs and pharmaceuticals, making the treatment of chronic illnesses like Alzheimer's and dementia more difficult [2].

Mechanism of Drug-Herb Interaction

A person's health, the medications they are taking at the same time, the drug or herb's therapeutic indicators, the surroundings, the administration method, and the timing of the medication have all been linked to the clinical significance of drug-herb interactions. Pharmacokinetic or pharmacodynamic processes may be altered as a result of drug-herb interactions. For example, when medications and herbal remedies are taken together, the absorption of the drug may be impacted if the two compete for gastrointestinal absorption or if the herbs cause the drugs to chelate. Herbs that induce or inhibit medication binding to transport proteins or plasma can also have an impact on drug distribution. Herbs can either support or inhibit drug-receptor interactions at receptor sites [2, 3]. Herbs have also been shown in studies to either stimulate or inhibit enzymes that either stimulate or inhibit metabolic processes. Herbs can also either increase or impede the renal clearance of medicines. The hepatic enzymes cytochrome P450 and the drug transporter P-glycoprotein help herbs induce or inhibit the pharmacological effects of pharmaceuticals. The main location of drugs taken orally is the villus tip of enterocytes, where P-glycoprotein and CYP3A are highly expressed. P-glycoprotein and cytochrome P450 are therefore essential for the bioavailability of many medications and herbs, and they may also be important in interactions between pharmaceuticals and herbs. Herbs and medications used for AD, as well as medications taken by AD patients for the treatment of other comorbidities like depression or cardiovascular disease, or medications used as supplementary therapy, can interact with one another. For example, ginseng has been found to interact with phenelzine, a monoamine inhibitor that has been suggested as an additional treatment for AD due to its neuroprotective qualities. When ginseng and phenelzine were administered together at a dose of 45 mg/day, patients experienced headache, tremulousness, and manic episodes, as well as insomnia and increased depression. The exact interaction mechanism is unknown, however, it might be due to ginseng's centrally located psychoactive effects [2 - 5]. Ginseng extract's saponins and other components inhibit nicotinic acetylcholine receptors, promote relaxation, and halt the activation of sodium ion channels in the brain that are voltage-dependent. In Germany, ginkgo biloba is a well-liked herb that is approved for dementia treatment. The many flavonoids, terpenoids (ginkgolides), and organic acids found in ginkgo are thought to function in concert as free radical scavengers, which is why many AD sufferers take it [6]. Ginkgo was shown to enhance cognition in a 2020 trial with no discernible negative side effects. As a result, ginkgo was approved for treatment in AD patients. However, it was later reported that a 70-year-old man who took a 40 mg pill of concentrated ginkgo experienced spontaneous hyphema. Later reports documented the occurrence of spontaneous bilateral subdural hematomas as a result of ginkgo consumption. Ginkgolide B, a strong inhibitor of a platelet-activating factor

CHAPTER 9

Research and Clinical Studies of Brain Boosting Herbs: The Ultimate Guide to Use Herbal Medicine for Dementia and Alzheimer's

Saloni Yadav¹, Shraddha Mahajan^{1,*}, Sweta S. Koka¹ and G.N. Darwhekar¹

¹ Acropolis Institute of Pharmaceutical Education & Research, Indore, Madhya Pradesh, India

Abstract: Dementia and Alzheimer's Disease (AD) are progressive neurodegenerative conditions marked by cognitive deterioration, memory impairment, and compromised everyday functioning. With the increasing frequency of these illnesses among aging populations, there is an urgent demand for effective, accessible, and safe therapeutic alternatives. Traditional medicine and ethnopharmacology have historically employed cognitive-enhancing herbs, providing a supplementary method to standard therapies. This chapter assesses the efficiency of protruding medicinal herbs, such as *Ginkgo biloba*, *Bacopa monnieri* (Brahmi), *Panax ginseng*, *Withaniasomnifera* (Ashwagandha), and *Salvia officinalis* (Sage), in the inhibition and management of dementia and Alzheimer's disease.

The research investigates its neuroprotective mechanisms, including antioxidant activity, suppression of amyloid-beta aggregation, cholinesterase inhibition, anti-inflammatory effects, and facilitation of neurogenesis. Clinical trials assessing the efficacy, safety, and dose of various plants are examined to evaluate their medicinal potential. Although preclinical and small-scale clinical trials indicate potential cognitive and neuroprotective benefits, limitations like variability in study designs, limited sample sizes, and inconsistent results require additional careful investigation. This abstract emphasizes the significance of merging traditional knowledge with contemporary evidence-based medicine to create innovative, plant-derived medicines that target the complex pathogenesis of dementia and Alzheimer's disease.

Keywords: Alzheimer's, Anti-inflammatory properties, Antioxidant properties, Clinical research, Dementia, Medicinal herbs, Neuroenhancing herbs.

* Corresponding author **Shraddha Mahajan:** Acropolis Institute of Pharmaceutical Education & Research, Indore, Madhya Pradesh, India; E-mail: Shraddhamahajan15@gmail.com

INTRODUCTION

Alzheimer's Disease (AD), an incurable neurological disorder, is characterized by a decline in memory and cognition [1]. Three-quarters of all cases of dementia are believed to be AD, the most common kind in the current situation, as depicted in Fig. (1) (Different Stages of AD). Furthermore, among individuals over 65, AD is the seventh most prevalent cause of death [2]. Dementia affects 51.6 million individuals globally, or 0.7% of the total population. Between 1990 and 2019, the total number of impacts doubled [3].




Fig. (1). Different stages of AD.

Alzheimer's disease accounts for about 80% of all dementia diagnoses [4]. Symptoms usually appear after age 60, and early versions of the disease are associated with a genetic abnormality [5]. Although the precise origin is uncertain, genetic factors are linked in 10–15% of instances [6]. Up until now, finding a cure for AD has been a miserable experience, and the drugs that are currently on the market only lessen the intensity of the symptoms. Traditional treatments, like cholinesterase inhibitors (donepezil, rivastigmine) and glutamate regulators (memantine) reduce symptoms to some extent but do not cure the illness [7]. Their inability to treat the development of the disease has sparked curiosity in complementary and alternative therapies, such as the use of herbal remedies. Studies on brain-boosting herbs have accelerated, driven by numerous clinical trials examining their effectiveness in improving cognitive function, preventing neurodegeneration, and promoting brain health [8, 9]. This chapter will deal with the herbs used in the treatment of dementia and Alzheimer's disease.

Overview of Alzheimer's & Dementia

The pathological characteristic of Alzheimer's disease is the accumulation of neurofibrillary tangles and amyloid beta ($A\beta$) plaques in regions associated with cognition [10]. Alzheimer's is a complex disease, with conserved variables, aging, and genetics; these all have a substantial influence on its pathophysiology, such as mutations in various genes, including APP, PSEN1, and PSEN2, that enhance $A\beta$ accumulation in Alzheimer's disease [11]. Cardiovascular problems, obesity, diabetes, and several lifestyle factors heighten the risk of Alzheimer's disease. The etiology of Alzheimer's disease is associated with multiple processes, including the accumulation of $A\beta$ plaques and neurofibrillary tangles, oxidative stress, neuroinflammation, mitochondrial dysfunction, and synaptic impairment [12].

Mechanism Behind Dementia

The main pathogenic processes of AD are as follows:

- **Amyloid Beta Hypothesis:** It projects that $A\beta$ accretion is crucial for Alzheimer's disease, followed by neurofibrillary tangles, vascular damage, dementia, and cell death. The $A\beta$ peptide is formed after a larger Amyloid Precursor Protein (APP) is abnormally cleaved. APP, a larger protein present in neuronal membranes, is the source of amyloid beta. Amyloid-beta peptides are created when the enzymes β -secretase and γ -secretase break down APP. In a healthy brain, amyloid-beta is effectively removed. Nevertheless, an imbalance between production and clearance may arise in Alzheimer's disease, which can result in the development of amyloid-beta oligomers, which are tiny aggregates. Formation of plaques, which are large, insoluble deposits that are extracellularly located in the brain [13].
- **Tau Protein and Neurofibrillary Tangles:** Two essential components of the pathophysiology of AD are the tau protein and the progression of Neurofibrillary Tangles (NFTs). These essentials are crucial to the tau hypothesis, which hypothesizes that dysfunctional tau protein plays an essential role in Alzheimer's disease neuronal malfunction and cognitive decline. Tau becomes hyperphosphorylated in AD, meaning that the addition of phosphate groups has abnormally altered it.
- The hyperphosphorylation of tau in microtubules results in impaired intracellular transport and microtubule instability. Tau masses form Paired Helical Filaments (PHFs), which in turn give rise to NFTs. Inside neurons, hyperphosphorylated tau protein masses form insoluble clumps known as Neurofibrillary Tangles (NFTs). The majority of these tangles are located in areas of the brain that are crucial for memory and cognition, such as the entorhinal cortex and hippocampus [14].

CHAPTER 10

Future Directions in Herbal Medicines and Nootropics as Cognitive Enhancers

Ravikant Gupta^{1,*}, Vaibhav Rajoriya², Sudha Vengurlekar³ and Sachin Kumar Jain³

¹ *School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India*

² *Vedic Institute of Pharmaceutical Education and Research, Sagar, Madhya Pradesh, India*

³ *Faculty of Pharmacy, Oriental University, Indore, Madhya Pradesh, India*

Abstract: The quest for cognitive enhancement has led to a resurgence of interest in both herbal medicines and synthetic nootropics. This paper explores future directions of these cognitive enhancers, delving into their historical context, mechanisms of action, and comparative efficacy. We examine popular herbal medicines such as Ginkgo Biloba, Bacopa Monnieri, and Panax Ginseng, alongside modern nootropics like Alpha GPC and Noopept. Emerging trends, including personalized nootropics and AI-driven formulations, are discussed, highlighting their potential to revolutionize cognitive enhancement. Additionally, we review recent clinical trials and research, addressing the challenges and ethical considerations in this field. This comprehensive analysis aims to provide a roadmap for future research and development in the realm of cognitive enhancers.

Keywords: AI driven formulation, Clinical trails, Cognitive booster, Personalized nootropics.

INTRODUCTION

• Overview of Cognitive Enhancement

Cognitive enhancement involves boosting cognitive functions such as memory, attention, creativity, and problem-solving abilities beyond their typical levels. Although the idea is not new, recent progress in neuroscience, pharmacology, and technology has led to innovative methods for enhancing cognition. Key areas of cognitive enhancement are:

* **Corresponding author Ravikant Gupta:** School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India; E-mail: ravikant491990@gmail.com

- Brain stimulation techniques: Techniques like Transcranial Direct Current Stimulation (tDCS) and Transcranial Magnetic Stimulation (TMS) are used to influence neuronal activity, leading to improvements in cognitive functions such as learning, memory, and attention.
- Nootropic substances: These include synthetic compounds (*e.g.*, modafinil, methylphenidate) as well as natural substances (*e.g.*, caffeine, omega-3 fatty acids) that are believed to enhance cognitive performance.
- Nutraceuticals and dietary supplements: Compounds such as vitamins, minerals, and herbal extracts are studied for their potential cognitive benefits through mechanisms like neuroprotection and neurotransmitter modulation.
- Ethical and societal implications: The use of cognitive enhancement technologies raises ethical concerns regarding safety, fairness, and autonomy. Issues such as access to enhancement interventions and potential disparities among different socioeconomic groups are also important considerations [1].

• Importance of Herbal Medicines and Nootropics

Importance of herbal medicines and nootropics: Herbal medicines and nootropics have gained significant attention in recent years for their potential to enhance cognitive functions and overall brain health. Here are some key reasons why they are considered important:

- Natural and accessible options: Many herbal medicines are derived from plants and have been used for centuries in traditional medicine systems around the world. They offer a more natural and often more accessible alternative to synthetic drugs for cognitive enhancement.
- Potential cognitive benefits: Herbal medicines such as Ginkgo Biloba, Bacopa Monnieri, and Panax Ginseng have shown promising results in improving memory, attention, and mental clarity. Nootropics, both natural and synthetic, are designed to enhance various cognitive functions, including focus, motivation, and creativity.
- Neuroprotective properties: Several herbal medicines and nootropics possess neuroprotective properties, which means they can help protect the brain from damage caused by oxidative stress, inflammation, and other harmful factors. This can be particularly beneficial in aging populations and those at risk of neurodegenerative diseases.
- Adaptogenic effects: Certain herbal medicines, known as adaptogens (*e.g.*, Rhodiola Rosea, Ashwagandha), help the body adapt to stress and maintain balance. This can improve overall cognitive performance and mental resilience, making them valuable tools for managing stress-related cognitive decline [2].

- Fewer side effects: Many herbal medicines are considered to have fewer side effects compared to synthetic drugs. This makes them a safer option for long-term use, especially for individuals looking to enhance cognitive function without the risk of severe adverse effects.
- Research and innovation: The growing interest in herbal medicines and nootropics has spurred extensive research and innovation in this field. Advances in technology, such as AI-driven formulations and personalized nootropics, are paving the way for more effective and targeted cognitive enhancers.
- Holistic approach to health: Herbal medicines and nootropics often promote a holistic approach to health, addressing not only cognitive function but also overall well-being. This aligns with the increasing demand for integrative health solutions that consider the body, mind, and spirit. In summary, herbal medicines and nootropics hold significant potential for cognitive enhancement, offering natural, effective, and often safer alternatives to traditional drugs. Continued research and innovation in this field are likely to uncover even more benefits and applications in the future.

Historical Perspective

Herbal medicines have a long and rich history, with their origins deeply rooted in ancient civilizations across the globe. These early societies harnessed the medicinal properties of plants to treat various ailments, laying the groundwork for modern herbal medicine practices. Traditional Chinese Medicine has a rich history of using herbs for cognitive enhancement and overall well-being. Ginkgo Biloba, for example, has been used for its memory-boosting properties. Ayurveda, originating in India, employs herbs such as Bacopa Monnieri (Brahmi) and Ashwagandha to improve mental clarity, reduce stress, and enhance cognitive function. Native American Practices: Indigenous tribes have utilized various plants, such as Ginseng and Sage, for their cognitive and medicinal benefits [3].

• Traditional Use of Herbal Medicines

Herbal medicines have been an integral part of traditional healing practices for centuries across various cultures. These natural remedies, derived from plants, have been used to treat a wide range of ailments, including cognitive disorders. Here are some key aspects of the traditional use of herbal medicines:

- Ancient civilizations and herbal knowledge
- **Traditional Chinese Medicine (TCM):** One of the most well-documented and enduring systems of herbal medicine is Traditional Chinese Medicine (TCM). Dating back over 2,000 years, TCM has utilized a wide array of herbs to

CHAPTER 11

Conclusion

Komal Kriti^{1,2}, Reetuparna Acharya³ and Smita Jain^{4,*}

¹ Department of Pharmaceutical Sciences, Dhanbad College of Pharmacy, Dhanbad, Jharkhand, 826004, India

² Faculty of Pharmacy, Oriental University, Indore, 453555, Madhya Pradesh, India

³ University Institute of Pharma Sciences, Chandigarh University, Mohali, 140413, Punjab, India

⁴ Department of Pharmacology, School of Pharmacy and Technology Management, SVKM's NMIMS Deemed to be University, Shirpur, Maharashtra, India

CHAPTER 1: INTRODUCTION TO MEMORY AND NEURODEGENERATIVE DISORDERS**Conclusion**

Memory and neurodegenerative illnesses are important research areas for understanding, diagnosing, and treating severe conditions [1]. Memory formation involves several brain areas, and neurodegenerative illnesses cause aberrant proteins in brain tissues to accumulate, impairing cognitive abilities, notably episodic memory. Neurobiological processes, diagnostic methods, and new therapies must be understood to advance the field and improve patient outcomes [1].

Memories are diverse cognitive functions that encode, store, and retrieve information. Neurotransmitters in the hippocampus and amygdala govern this complicated encoding, storage, and retrieval process. The capacity of synapses to increase or decrease neuronal connections is critical for memory formation and is typically disturbed in neurodegenerative illnesses [2].

Memory Formation has Three Phases

- **Encoding:** Turning sensory information into a brain-readable memory trace.
- **Storage:** Moving hippocampus-encoded memories to the cortex for long-term storage.

* **Corresponding author Smita Jain:** Department of Pharmacology, School of Pharmacy and Technology Management, SVKM's NMIMS Deemed to be University, Shirpur, Maharashtra, India;
E-mail: smitajain1994@gmail.com

- **Retrieval:** Retrieve information from memory locations spontaneously or in response to external events.

Several brain areas are crucial to memory.

- **Hippocampus:** Processes new experiences into long-term memory, encodes and stores them, and integrates contextual and geographical information.
- **Amygdala:** Deals with emotions and consolidates memory.
- **Thalamus:** Filters sensory input and encodes contextual information for strategic memory recall.
- **Prefrontal Cortex:** Controls memorization, working memory, and context recall.
- **The Cerebellum:** It influences procedural memory and motor learning, fine-tuning motor movements based on past experiences.
- **Basal Ganglia:** Through reward-based learning, the basal ganglia automate abilities, consolidate habits, and link actions to favourable outcomes.
- **Hypothalamus:** Arousal, attention, and motivation in the hypothalamus affect memory.
- **Brainstem:** Sorts memories by urgency and affects memory retention under intense emotions.
- **Temporal Lobe:** Stores and produces long-term memory.

Memory development, storage, and retrieval depend on neurotransmitters including glutamate, acetylcholine, and dopamine. Cognitive decline may result from neurotransmitter imbalance or neuronal dysfunction, particularly in neurodegenerative diseases [3].

Neurodegenerative Disease Types and Characteristics

Neurodegenerative disorders cause gradual, progressive neuron degeneration owing to aberrant protein buildup. These disorders decrease cognition, especially short-term and long-term memory. Neurodegenerative disorders include protein misfolding, neuroinflammation, oxidative stress, and genetics. Cognitive, motor, and behavioral abnormalities are common [4].

Several Neurodegenerative Disorders Impair Memory and Cognition

- **Alzheimer's Disease:** Memory loss and cognitive impairment caused by beta-amyloid plaque and tau protein neurofibrillary tangles.
- **Parkinson's Disease:** Degeneration of dopamine-producing neurons causes motor and cognitive symptoms.
- **Amyotrophic Lateral Sclerosis:** Motor neurons weaken, atrophy, and paralyze.

- **Huntington's Disease:** A mutation in the Huntingtin gene causes chorea, cognitive impairment, and mental symptoms in Huntington's Disease.
- **Prion Diseases:** They cause fast cognitive decline, memory loss, and movement impairment by abnormally folding brain proteins.
- **Multiple System Atrophy:** Multiple brain areas degenerate, causing balance, urinary, and speech problems.
- **Spinocerebellar Ataxia:** Cerebellum damage, speech ambiguities, and eye movement irregularities cause gradual coordination loss.
- **Lewy Body Diseases:** Alpha-synuclein protein deposits in neurons cause cognitive fluctuations, visual hallucinations, and Parkinsonism.
- **Friedreich's Ataxia:** A hereditary coordination impairment that causes gait instability.
- Multiple brain traumas cause chronic traumatic encephalopathy, which causes learning and impulse control problems, memory loss, and mood swings.
- **Frontotemporal dementia:** Degeneration of the frontal and temporal lobes causes severe behavioral changes, emotional instability, and communication problems.
- **Vascular dementia:** Reduced cerebral blood flow causes cognitive issues, including thinking, planning, memory, and concentration.
- **Multiple Sclerosis:** An autoimmune disease that attacks myelin, causing tiredness, mobility problems, numbness, and cognitive issues [5].

Neurodegenerative Disease Memory Dysfunction

Many neurodegenerative disorders, including dementia, cause memory loss. AD causes hippocampal degradation and cerebral cortical atrophy, affecting memory and cognition. People may repeat inquiries, have trouble with previous discussions, or become lost in familiar settings. Cognitive impairment from illness development makes it hard to remember prior events [6, 7].

Different Neurodegenerative Illnesses Affect Different Kinds of Memory

- **Episodic Memory:** AD, ALS, frontotemporal dementia, prion disorders, and spinocerebellar ataxia mostly impair it.
- **Working Memory:** Parkinson's, spinal muscular atrophy, Lewy body, chronic traumatic encephalopathy, Friedreich's ataxia, vascular dementia, and multiple sclerosis influence working memory.
- **Procedural Memory:** Parkinson's and Huntington's disease severely impair procedural memory.
- **Short-term Memory:** Multiple system atrophy, Friedreich's ataxia, chronic traumatic encephalopathy, and vascular dementia affect short-term memory.
- **Long-term Memory:** Multiple system atrophy affects long-term memory.
- **Semantic Memory:** In prion illnesses, semantic memory is preserved less.

SUBJECT INDEX

A

Acetylcholinesterase inhibition 38, 55, 185, 191, 193
 Acetylcholinesterase inhibitors (AChEI) 31, 68, 168, 202, 203
 Acetylcholinesterase (AChE) 54, 55, 61, 66, 69, 138, 167
 Activation 29, 55, 61, 68, 69, 70, 73, 142, 162, 259
 Active compounds 75, 113, 184, 186, 188, 190, 192, 194, 196, 221, 227
 Activities of daily living (ADL) 185
 Adaptogen 115, 117, 119, 188, 195, 196, 199, 218, 226
 Adaptogenic properties 43, 44, 117, 190, 225, 226, 227, 228
 Attention-deficit/ hyperactivity disorder (ADHD) 38, 45, 48, 188, 199
 Adverse effects 82, 83, 119, 149, 202, 204, 206, 207, 247, 252, 259
 Agitation 84, 86, 87, 88, 89, 92, 93, 95, 99, 104, 105, 106, 200, 202, 255
 Alkaloids 38, 60, 69, 71, 160, 167, 186, 190, 249
 Alpha-gpc 229, 248, 259
 Alzheimer's disease assessment scale (ADAS) 191
 Amyloid plaques 27, 61, 72, 82, 122, 139, 150, 151, 153, 169, 181
 Animal models 74, 120, 140, 147, 148, 149, 151, 152, 153, 172, 195
 Aniracetam 37, 40, 42, 46, 222, 231
 Anti-inflammatory effects 60, 61, 63, 67, 68, 69, 70, 73, 117, 118, 187, 189, 191, 193
 Antioxidant activity 41, 60, 63, 66, 67, 68, 69, 178, 184, 189, 193
 Antioxidant properties 38, 41, 73, 75, 166, 169, 186, 187, 189, 191, 196, 198, 201
 Amyloid precursor protein (APP) 27, 30, 72, 73, 80, 134, 136, 137, 138, 150, 151, 180
 Ashwagandha 43, 62, 115, 116, 117, 118, 119, 120, 121, 122, 129, 183, 191, 228, 251

Ayurveda 113, 114, 115, 116, 117, 118, 123, 163, 164, 219, 220, 251, 252, 253, 255

B

Blood-brain barrier (BBB) 40, 42, 53, 74, 137, 138, 143, 144, 145, 147, 171, 249, 256
 Brain-derived neurotrophic factor (BDNF) 40, 43, 45, 55, 61, 63, 64, 65, 70, 121, 224, 229, 250
 Behavioral and psychological symptoms of dementia (BPSD) 258
 Bioavailability 74, 75, 162, 189, 252, 259
 Biomarkers 15, 26, 75, 123, 189, 245, 246
 Brahmi 61, 115, 116, 117, 118, 119, 120, 121, 123, 129, 219, 220, 249, 251

C

Centella asiatica 37, 38, 64, 115, 117, 118, 121, 122, 129, 198, 249, 251, 255
 Cerebral blood flow 184, 201, 223, 225, 227, 228, 257
 Cholinesterase inhibitors 15, 31, 71, 81, 82, 179, 182, 201, 203, 247, 252
 Clinical trials 47, 48, 63, 65, 122, 127, 128, 129, 187, 189, 233, 248, 254, 256, 257
 Cognitive enhancement 48, 49, 116, 217, 218, 219, 221, 222, 223, 231, 232, 236, 237, 238, 239
 Cognitive training (CT) 15, 82, 83, 234, 235, 245, 250
 Convolvulus pluricaulis 115, 118, 122, 129, 167, 251, 255
 Curcumin 41, 42, 63, 64, 70, 71, 72, 73, 74, 168, 188, 189, 190

D

Damage 56, 118, 119, 120, 121, 122, 139, 142, 184, 187, 197, 223, 224, 225
 Donepezil 31, 38, 45, 46, 59, 163, 174, 179, 182, 201, 203

Dopamine 2, 7, 8, 39, 45, 69, 226, 227, 229, 243, 251

Drug-herb interactions 161, 162, 163, 203, 204

E

Efficacy 48, 49, 121, 122, 124, 125, 126, 127, 128, 201, 203, 206, 207, 208, 231

Embryonic stem cells (ESCs) 141, 146, 253

F

Fatty acids 37, 38, 42, 43, 167, 169, 170, 218, 248

Flavonoids 60, 62, 68, 69, 70, 71, 72, 160, 162, 167, 184, 195, 196, 198, 199

Free radicals 41, 42, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 119, 120, 226

G

Gamma-aminobutyric acid (GABA) 6, 37, 39, 40, 141, 229

Ginkgo biloba 37, 62, 185

Ginsenosides 64, 65, 73, 196, 197, 227, 258

Glutamate 2, 6, 29, 39, 40, 138, 224, 243, 246

Gotu kola 64, 115, 117, 118, 119, 120, 121, 122, 123, 198, 199, 249, 251, 252, 255

H

Herbal medications 204, 249, 250, 256, 257, 258

Hippocampus 1, 2, 4, 5, 6, 8, 9, 98, 99, 140, 141, 242, 243

Huperzine 38, 39, 43, 44, 66, 71, 248

I

Induced pluripotent stem cells (iPSCs) 141, 142, 143, 145, 146, 253

Inflammation 41, 42, 55, 56, 70, 71, 73, 171, 172, 173, 174, 188, 189, 220, 221

Insulin resistance 171, 255

L

L-theanine 37, 38, 40, 41, 43, 44, 229, 230, 248, 259

M

Mechanisms 39, 40, 47, 48, 49, 61, 62, 67, 113, 119, 121, 136, 137, 223, 224

Memory formation 1, 2, 4, 5, 6, 7, 9, 15, 223, 226, 242

Mesenchymal stem cells (MSCs) 141, 253, 254

Microfluidics 140

Microglia 21, 29, 30, 31, 58, 72, 139, 141, 151, 152, 246

Mitochondrial dysfunction 12, 30, 31, 53, 54, 58, 138, 148, 180, 247

Modafinil 37, 39, 41, 45, 46, 128, 218, 231, 248

Music therapy 84, 85, 86, 87, 89, 90, 104, 105, 106, 107, 250

N

Nerve growth factor (NGF) 40, 43, 55, 138, 143, 229

Neurodegenerative diseases 1, 2, 3, 7, 14, 15, 21, 53, 55, 70, 74, 75, 117, 147, 235, 252

Neurofibrillary tangles (NFTs) 7, 8, 9, 27, 28, 29, 30, 81, 82, 135, 136, 137, 149, 180, 246

Neurogenesis 42, 43, 119, 121, 169, 178, 187, 189, 195, 251, 257

Neuroinflammation 7, 8, 28, 54, 55, 57, 58, 63, 64, 72, 148, 149, 181, 253, 255

Neuroplasticity 15, 48, 49, 63, 64, 98, 104, 195, 205, 250

Neuroprotection 37, 40, 41, 73, 74, 75, 122, 123, 223, 224, 225, 226, 227, 228, 247

Neurotransmitter levels 46, 49, 119, 189, 223, 225, 226, 227, 259

N-methyl d-aspartate (NMDA) 29, 137
Noopept 37, 40, 42, 217, 229, 231, 248, 259
Neural stem cells (NSCs) 141, 142, 145, 253, 254

O

Oxidative stress 168, 259, 64, 66, 69, 70, 249
Omega-3 37, 38, 42, 43, 45, 218, 248

P

Panax ginseng 37, 64, 196, 197, 201, 217, 218, 227, 228, 231, 257, 258, 259
Pathogenesis 8, 9, 10, 67, 68, 134, 136, 137, 140, 253, 254, 255, 256, 257
Personalized medicine 47, 48, 123, 124, 128, 130, 248, 252, 254, 258, 259
Pharmacokinetics 162, 202, 206, 207, 249, 255
Phytochemicals 53, 54, 55, 70, 71, 160, 161, 168, 250, 255, 257
Piracetam 37, 39, 42, 44, 45, 46, 47, 222, 223, 224, 229, 231
Pro-inflammatory cytokines 63, 64, 65, 67, 68, 69, 70, 181, 193, 246
Presenilin 1 (PSEN1) 56, 136, 137, 138, 151, 180

Q

Quality of life 31, 32, 83, 84, 93, 95, 104, 105, 106, 107, 207, 247, 248, 250, 251

R

Randomized controlled trials (RCTs) 185, 187, 189, 191, 193, 197
Reactive nitrogen species (RNS) 30, 58, 70, 249
Reactive oxygen species (ROS) 26, 29, 30, 31, 54, 55, 58, 60, 67, 68, 70, 138, 171, 181, 246

Rhodiola rosea 37, 39, 194, 195, 196, 202, 218, 222, 226, 227, 231, 258, 259
Rosmarinic acid 65, 66, 192, 199, 200

S

Salvia officinalis 65, 178, 192, 193, 249, 257
Scavenging 65, 66, 67, 68, 69, 70, 75
Sensory stimulation therapy (SST) 103, 104, 105, 106
Shankhapushpi 115, 118, 119, 120, 122, 123, 129, 251
Side effects 30, 31, 32, 128, 130, 161, 185, 202, 203, 204, 219, 222, 254, 255, 256
Synaptic plasticity 42, 43, 58, 61, 63, 65, 69, 187, 191, 197, 224, 226
Synthetic nootropics 37, 41, 217, 222, 224, 229, 230, 231, 232, 259, 260

T

Traditional chinese medicine (TCM) 41, 219, 224, 227
Tau proteins 8, 9, 20, 22, 28, 29, 30, 31, 64, 66, 68, 136, 137, 138
Thiamine 171, 172
Transgenic models 134, 149, 150, 152, 254

V

Vascular dementia 5, 9, 13, 14, 22, 56, 62, 66, 81, 82, 244
Vitro models 140, 141, 144, 145, 147, 152, 253

W

Withania somnifera 38, 46, 62, 228, 249, 251, 255, 257, 259
Withanolides 43, 62, 63, 190, 191
Working memory 3, 6, 7, 8, 14, 45, 46, 49, 120, 122, 243, 244



Sachin Kumar Jain

Dr. Jain is currently positioned as Professor & Principal at Oriental College of Pharmacy & Research, Oriental University, Indore, MP (India). Dr. Jain has 20 years of teaching experience. He has received the Best Researcher Award, Best Pharmacy Professional Award, and Young Talent Award at various national and international conferences. Dr. Jain has published more than 16 books with various reputed publishers, including Bentham Science, Taylor & Francis, IGI Global, Apple Academic Press, Iterative International Publishers, and many more. Dr. Jain is an active peer reviewer for various national and international journals with high impact factors and reputed publishers. Dr. Jain has published more than 135 research/review articles in national and international journals with good indexing. He has also published more than 32 book chapters with international publishers (Bentham Science, Springer Nature, Taylor & Francis, Cambridge Scholars Library, Iterative International Publishers) with good indexing. Under his supervision, 6 Ph.D. degrees have been awarded. His research interest is in the assessment of various phytopharmacological activities of plant drugs and the development of herbal extracts.



Kratika Deniel

Dr. Daniel is a distinguished academician and researcher with over 17 years of experience in pharmaceutical and medicinal chemistry. Currently serving as Professor and Associate Dean (Research) at the Faculty of Pharmacy, Oriental College of Pharmacy & Research, Oriental University, Indore, she holds a Ph.D. from Mahatma Jyoti Rao Phule University, Jaipur, with expertise in drug design, phytochemistry, and natural products. Dr. Daniel's research output is prolific; she has published 97 research papers in reputed national and international journals, authored 15 books, and filed 11 patents, of which 2 have been granted, including one on AI-enabled molecular modeling for ligand-receptor docking. She has guided 10 Ph.D. scholars, 30 master's students, and over 50 undergraduates throughout her career. Recognized for her contributions, she has received several honours, including the Young Achiever Award, Distinguished Professor Award, Best Innovator Award, and the Inspirational Associate Professor Award. She is an approved Ph.D. supervisor at Oriental University and Mandsaur University, a registered pharmacist with the M.P. Pharmacy Council, and a life member of APTI, IPA, IACP, and Vigyan Bharti. She is also a reviewer and editorial board member of numerous national and international journals.



Sudha Vengurlekar

Dr. Sudha Vengurlekar, Dean, Faculty of Pharmacy, Oriental University, Indore, is a distinguished academic leader with over two decades of experience in pharmaceutical education, research, and institutional administration. She possesses comprehensive expertise in healthcare systems, regulatory frameworks, and drug development processes. Her research interests encompass antimicrobial drug design, herbal drug development, and molecular modelling, supported by proficiency in healthcare technologies and data analytics. She has made substantial scholarly contributions, including approximately 90 research publications, 30 book chapters, and authorship/editorship of six academic books. Dr. Vengurlekar has successfully obtained research and academic grants from national bodies such as AICTE, PCI, and ICMR, and has been instrumental in fostering academia-industry collaborations. She is actively engaged in scientific committees and editorial responsibilities, contributing to the advancement of pharmaceutical research and education.